var title_f7_8_7296="UGI-SMA syndrome II";
var content_f7_8_7296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    UGI dilated stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is the UGI study on the same patient demonstrating the dilated stomach (open arrowhead) and a dilated proximal duodenum (closed arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7296=[""].join("\n");
var outline_f7_8_7296=null;
var title_f7_8_7297="Cetiedil: International drug information";
var content_f7_8_7297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cetiedil: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fusten (GR);",
"     </li>",
"     <li>",
"      Huberdilat (ES);",
"     </li>",
"     <li>",
"      Stratene (FR, IT, LU);",
"     </li>",
"     <li>",
"      Vasocet (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Cetiedil Citrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of peripheral vascular disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Adults: 400-600 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, as citrate: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10355 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7297=[""].join("\n");
var outline_f7_8_7297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323558\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978247\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978249\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978252\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978248\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821230\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978251\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10355|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_8_7298="Port placement for TEP hernia repair";
var content_f7_8_7298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Port placement for TEP hernia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7298=[""].join("\n");
var outline_f7_8_7298=null;
var title_f7_8_7299="Normal anatomy of the mandible";
var content_f7_8_7299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F71316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F71316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Normal anatomy of the mandible",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7299=[""].join("\n");
var outline_f7_8_7299=null;
var title_f7_8_7300="Autoeczematization on hand";
var content_f7_8_7300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Autoeczematization (id reaction)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous vesicular papules are present on the hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7300=[""].join("\n");
var outline_f7_8_7300=null;
var title_f7_8_7301="Fibrinoid nec flood vessel";
var content_f7_8_7301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrinoid necrosis within blood vessel wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fibrinoid necrosis within the blood vessel wall of an artery/arteriole supplying a peripheral nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7301=[""].join("\n");
var outline_f7_8_7301=null;
var title_f7_8_7302="Pseudoephedrine and codeine: Drug information";
var content_f7_8_7302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pseudoephedrine and codeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/33/14869?source=see_link\">",
"    see \"Pseudoephedrine and codeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6808425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Codar&reg; D;",
"     </li>",
"     <li>",
"      EndaCof-DC;",
"     </li>",
"     <li>",
"      Notuss&reg;-DC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6808429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive/Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6808487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of congestion and cough:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Products listed in dosage forms may contain differing amounts of active ingredients; however, the dosing volume and frequency are the same: 5-10 mL every 4-6 hours as needed (maximum: 40 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6808486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of congestion and cough:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Products listed in dosage forms may contain differing amounts of active ingredients; however, the dosing volume and frequency are the same.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6-11 years: 2.5-5 mL every 4-6 hours as needed (maximum: 20 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6808488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6808489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Codar&reg; D: Pseudoephedrine hydrochloride 30 mg and codeine phosphate 8 mg per 5 mL (473 mL) [contains propylene glycol; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     EndaCof-DC: Pseudoephedrine hydrochloride 30 mg and codeine phosphate 10 mg per 5 mL (473 mL) [dye free, ethanol free, gluten free, sugar free; contains propylene glycol; fruit gum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Notuss&reg;-DC: Pseudoephedrine hydrochloride 30 mg and codeine phosphate 10 mg per 5 mL (473 mL) [dye free, ethanol free, gluten free, sugar free; contains propylene glycol; bubblegum flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6808427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F6808423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liquid: C-V",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6808432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary symptomatic relief of congestion and cough due to upper respiratory infections including common cold, bronchitis, sinusitis, and influenza",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14199157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6808443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Arrhythmia, heart rate decreased/increased, hypertension, pallor, palpitation, tightness of chest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Confusion, coordination impaired, dizziness, drowsiness, euphoria, excitation, fatigue, headache, hysteria, insomnia, irritability, lightheadedness, nervousness, neuritis, restlessness, sedation, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Photosensitivity, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Early menses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, epigastric distress, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Dysuria, polyuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Acute labyrinthitis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Dyspnea, nasal congestion, thickening of bronchial secretions, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6808438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pseudoephedrine, codeine, or any component of the formulation; with or within 14 days of MAO-inhibitor therapy; severe cardiovascular disease (eg, hypertension, CAD, ischemic heart disease); newborns; premature infants; breast-feeding; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6808439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with mild-to-moderate cardiovascular disease (including hypertension, CAD, and ischemic heart disease); contraindicated in patients with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD, or other obstructive pulmonary disease; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with chronic ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;ultrarapid metabolizers&rdquo;: Use codeine with caution in patients with two or more copies of the variant CYP2D6*2 allele; may have extensive conversion to morphine and thus increased opioid-mediated effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough control: Not recommended to use for cough control in patients with a chronic cough due to asthma, emphysema, or smoking. Should not be used in patients with excessive secretions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Patients should notify healthcare provider if symptoms do not improve within 7 days or are accompanied by high fever. Patients should not exceed recommended doses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6833926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6808455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease codeine levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression). Avoid ephedra, yohimbe (may cause hypertension).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6808433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6808434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Codeine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6808436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6808437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Codeine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Codar D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-8 mg/5 mL (473 mL): $84.37",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nucosef (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6808460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pseudoephedrine directly stimulates alpha-adrenergic receptors of respiratory mucosa causing vasoconstriction; directly stimulates beta-adrenergic receptors causing bronchial relaxation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine is an antitussive that controls cough by depressing the medullary cough center",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6808462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9495 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7302=[""].join("\n");
var outline_f7_8_7302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854552\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808425\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808429\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808487\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808486\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808488\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808489\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808427\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808423\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808432\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14199157\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808443\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808438\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808439\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299960\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6833926\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808455\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808433\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808434\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808436\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808437\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321870\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276699\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808460\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6808462\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/33/14869?source=related_link\">",
"      Pseudoephedrine and codeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_8_7303="Palpation radial styloid";
var content_f7_8_7303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67845%7ERHEUM%2F56635%7ERHEUM%2F58422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67845%7ERHEUM%2F56635%7ERHEUM%2F58422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the radial styloid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wrist is placed in a neutral position with the radial side up. The most distal portion of the radial styloid is identified, marked, and palpated for local tenderness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resisting thumb extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 276px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEUAXEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCJRmpApqJDnFTKaDAQL7U1lxUp/wA4ph9M0FEezcwUcE8fSvTfC1qLOzTyjliOT69a8zY98813/g/VozaiORjvUd/xqZbDidfuLct3p0YLHA5NV/OjbkMcVW1TxFZaRaO7ZdwOAo78+1ZSkkrsta7G5Faqo3zMFUdcnFK2tWUDbId0rf7IyPzridCl1PxQxvLx2t7Bj+7iBwWHuK7G2tLe1TEEaqB3FRFyqK+yBxs7MJdZv5hi1tUUHjcTVGWDUrs5ub3y1P8ACqA1p/WoJHxT9lHrqG2xSh0iyibdJmV/U5FX1lihGI0x+Oar5J6Um0mqSUVoO7ZO90x4FU7mbCnPJqdlOOmfQCqrWVzcN8q7VPr6VLu9hozGmjDZk5+lWre/h4VYCfzrRg0eGMZuGBq/EtpER5a5YUlG3UbZmpM0g4tf1NTNuCNuh2j2NayMT0GB7U26jIiJycU7COB1qNTMrR8HvXLfEC33adDLjBGf611fiP8AdyCVCOOT69q5TxpeLd6YgRcKB/jU9RM4Aimkc8VLgc56U0j9a2JIsc0uMGnEcUD8qLDGYxS49velx65zXO+LdbbTIQsQ/eN3H4UJNsTdkdD8v94Z+tJgH/6wrxibXtReTd9oYZOetX9O8YXtswErGRR15rT2E0ri5j1Qr7U1sBhWFofie01QiMZSY9sf/WrtLTQrmdRI7LHGR3PNZ8stiro0PA8Ae7eQ5woFeiacu59x6VzPh3T0sY22tuyMZrr7BMIOO1dFONo2Oabu7mjAuR3q6mcDPNVoB0q2O1a3IsKRgVGwwvJqUD3/ACpsgAHNNCKkjc04j93Uch+agn5KAM67Tfu4NRaYdspFX2jyhzVGIFLnvg1Mho6WAjAOKtp0qhat8oq+h5B5pgSHpzVab9askd6rS4zTEiH8DRTqKBnhUbe9TI2Kpo3bvU6MDXLc3tYsg8UhPpTA3HXrTs/jTAace9LFNJA++JtppGPNMbkcdKT8wv2N+HxRLHDtmAyO+P8A61XPCRi8U63JBLjyoeWwOTnGP51x7DPbPavSPh3p6afbNcIB5kuCxHfpWMqabuaxkdzBFHbRLFEMIowBQ0nPtUDSk8etSQIZOTgL3JOKYEi5I7/hSrbF/vHHqc1m6v4i07SI2DyCSVQcIvP9a4y38Ta54r1CS30mJrWzjO1pDk5/zmsZVoxdlqylCUteh6LIbK1Gbm5jQe5qu2t6YjYgDXB/2DWdp3heCDEl5K9xMepLHH5VrLBFENsUaD/gIq1zvV6CskU5tcnbi309x6FhUQudVuf4VjU9sYrSSIZBwKuwxHGQP0quXuwMy30+VuZ5WOfetK3to48YB47mpcbRycU0SoGwPmNOyQFpFHAApZ4w8ZFLbsHPPQVLJJgYC8etRKXRAcB4psvkZlHOMH9K4DxZFHDpYCn5j2r2DXIPOgfocj0+leF+LWnF6Y5SdoPFK2oHOEdfSkxx9KkwaaV962QiMjg0Yp5HB7VGoI60mADr0/OuC8flEKl+6/4V3vXFcR8UIFGnxSE4bIwPXpVw3FLseZFjn2oGSMAZptXdLm+zXcczJvQEBgfSt4OUna4PRE/h+ET6gkfniBz91ycDNeo6J4xubC7TTNWmR16JIvQ9fauX8R+GYbrTF1fRiMEAyRr2PtiuV0jzbzV7OJ3ZmMgAJ61o3FR5Xv0Zi1ze8mfXPh799bow+6elddbIFUcVz/hW08nTbdcchRXTxrgADpSsZXJ4uvSrKjJFV48CrcP0prUBQNvNRyjg+lWtoPNVpwcHHSmIz5AN5FNFOlyCQKaoOc1IEhAKEYrOdMXGcd60j93BNVJFBkBxSHc0bVuBitOJht6Csq1OMCtOM8DjiqQE5Gc9KrSDnj9as9R61BKDzTEV/wAKKKKVxnz8jYNWIzyKpoc1YjauU3LiGngg1Ah96lB4z+lMQpPSoyQef1p5z2pjGkO4xjjBr1HwPOj6XGueR+nSvLj+GK09F1qbTGwPmQ9RUyKi7HsMsyQgsRux0ArMuZL+/Gzzjb2/91ec1hWXiWC4iHmEK3p/kVDqHiSJEP7wKO5H/wCqsJyXU0SbJtRsbOF0hhXzJnIBOSe9d7pel2en2UQtIVQMAWwO+B7V594NMuqX/wBr2bbZD8pPVjxXocEzCIA9BShG/vFSutCwzDHNRE5b3qKSUY9KqvcAZrVIk1U8tTl8fnTZtQRBtjGW7YrIVpbg4HT61r2FiEAZhlvWjV7Cduo2C3ubo5kYqvp61eWC3tl+cjP93PWsjWPE8FlMtna/vLpuvB+X9KS2Jcbpm3SnqT2rJSu7IFfc2FudxAACr6CpzMuzDc1kxyqhwVOfWrEVyG/h98VagMfceTIpwozXj3xK0srMLqJMAE7hj616zMRneWK8dBXNeLrQX2lTiMguFPT6GqcWI8MI5PXNNI7mp5kKTSIQQysQfzNRkU0hEX0ppyRzUxHNRkUILjFXc4HqcVwHxel2SWdup6LuI/AV6TYx77kE8hRmvIviXP8Aa9YkftGNo/Stacbq5MnqkcTWt4d8iS9EF0AUk4BPr2rJqRAwG9TgqQa0pScJXRU1zKx1Z1G80GWXTd5a3f7uehFW/AmgXE3i+xkaPMIffn865q/1Br2GJpP9bHx+Fe0/BmRdS8mXAzHwf/Hq3rJXVjn1Udj3LTYhHGNo4HH61prz0qCBNq8VbQd8/lUEApwatxH0qp35qzb84piLyHiq9wODUydOajm+ZaYGZKpyfXrQo+XpU0ikt70uzApARsPl4/GqrDnPNXXXPfI7VAwpWHcktTjGTWlFyOtZcQwwrRtn7d6ErCLgFMnAK1Ip6d6STG38KsLlLFFS4ooGfN6H8qsx9eKqpyRVmMVxnQrFpD/kVIvTrUScjr7VIOmM0CH5yKae9HbrRjjrQLQZjA/pTetPNMNIpCe4OPpToIFuZ0ibkMcHNNNSQSGGZJB1FJxvuik7Htfh60jtdNhjjUABe1aBO3isrw7epNYRZcHj1rSlYe3PvU2LIpm3ZH5063tXmbJBC00NEh3SMBj3rG8QeMbXS4WCuuccAEf40m1FXkwV27I6ie6stLtzJPKiKo5JP+fSvHPiT8XljE1h4fcSOMqZV5A/ziuG8eeNtQ1lnt45WSJiRgE9Off3rl9C0OfVbjbHkZOXcjP9K4amIc3yx2OyjhOsxuna/qllfC9a4llmbruOc/pX0H4A8YQ6zaxh5As44KnrmvNLXwNbQukwmDSJyBt/pimXcNzoet2t9YqVBYB1XgHpUwbg9DfEYd8t3ofSMTJcp8jYce9TwblA+TmuF8L+IPtsEbhgJABkZ+nvXcwy74ldDnIr0Iu55r0JZYxKvzKRmsi4g8skr0PaugiYlOgzVW6B/wCWiAr7dqtCPEfHmk/YtSNxGpEUvJ9utctjrXtHjjRRqWkSPaDLoC2Mc968ZKsMhgQ2cEEYpNaiuRnrTGHHpUhphH61NgLEGIdPuZzxhTzXiHikmQSSnqxz/Kva9d/0fwy5HBbFeK+JTi2x/ntXVTWiRle8jlav6bB56TjGflqhW3oJWO3nkboKUFdmk3ZGMQUYg9RxX0D+zhZMbC4uWztLkD8m/wAK8AnYPKzDoTX1Z8CNPFn4NtmI+aT5jx7vVR30M6r0R6gg61ZUYUdKgjznIqfPvWhgMZuRU9u2G61Xk4PTk1PbUhF4HjNROeafnikYA+3vVWGQY5pdvGRT8Up9xSAhIqGQD0q0QCKiZeuaAK6/e5/CrkDEdKqtwakRjilsBpxyetKSSfeqkchzg9quQgtyvNUAnl+9FW9relFKzA+Yo145qwgwR60xB69KnUdCK5bG9xyjn0p9NA45FOGAeadgYd6Ue9IqsxwASau21hJJgvlRUylGO7Lp0p1HaKKR/wA4pDnPvXQR6dGBwmcVPBbQsSTEOPasHX7I7oZfJ/EzmAjdACRQ0bgZKn8q7JIIFPEeKSeGJkJAU/So9vJ9C1l6W8jn9L8WDSFEU7Ns9R/+uup0vxrZ3Yws+fb8q4fxLo6TowUYJH+NeX6zp+oaddbrR5FAJPyms3VmnrsbLAQkrRlqfQWu+IYhCdsrAfQ+1ec6zLcXwdrYFuOCSa8ykvNauCEaWUj0zW9pFtrZjGJpAO2SKmU1J+9t5DjgakFeLVy5aaTdyykzR/MTyTXfeFrBLOzAYDcxGTXN2UGrp947/rXQadcOqCOUbXHBFR+7+ze/mb0adZT/AHiVvI6eVUSPMbE+uRWdfKt1HtAXd2qRblBCRlapWche5Ve2etJNqSsddelz0yDS72TTLzJJAzyPxr1zwvqsV5bIoYk5H8q8v1C0WVsqMN60/Q9Vl0a6CTZEZPU9q6nVSe+p8/KhKPoe7lnb5VOEHp3pJseWRGMnHJqho16l7YLNE4bPcfjWggLIe2e5roi7q5g9DH3SJckqMqfvLXm3xF0JbSYX9ooEUhG4DsTivWp7YKjMmWbvXM6xB9vs5baVcE9vfimxPXY8TYdx0oiTzJVUdzU95btbXUkLA5U4/lU+kQebdDjgf/WotfREt2Rl/EKT7Po0UQPBxXifiMloc9v/ANVe9/FCwMmhCRRypFeB+JpFSCGIdTyf0ro2Mo6s5yp1uHW3MKnCscmoKKzTsbtXHxIZJUQdWIFfaXw6tvsnhiwi6EIP5tXx/wCF7Y3evWUIGcvn8q+2NBh8nT4ExjauMfia0powrPWxrrwuacjHjPWombjApIpMferQxJJmG+rcHQe9ZjkmZcVrwj5R+tAEqke4FGM0Z9KU/SmhiHp1phySBTj05x+FJ16UWEAHpSMuR/Klzg9OvrTwQeaNxkDRZFMWFgeOtXFIzzU67StFguVIVI4Na2nqm35vvUttaiU/L1pJ7d4XBXPFAi95Y9qKoeY1FMLHzUnHuakU/hUSe1SD2rkOgeOnOantrd5mH931qFELAHtW1EyRQrwBXPWrcuiPQwWEVZ80tie2t44lGFy3rWhAYlILn8M1lG+SMZyPzqnLqkaZMZy31rkc+rPcjQSXLFG/qd3FAuVYZ9Kq6XcpKjBn2n1zXKXdzLcuXll2r6ZzSWl2iA7nJ/GpU3fXYp0Uo26nayGZciJkYH1FU3nlj5dOPQVzo1UofkLf99Go5NRuZm+RTj3NXzroYqk07G3LOtwx+VgfQmqlxYJOcuoNU7S9ulzvAP4VbttRLlhLxj2p+0B0tRLbQrfzN21QT7VvWelQqmQOfrUNjNayDBbDVceVFUhH6UudMlxadkTLaKozgAetc54rtvs0kd1EMhuGxWwbnjJeqGuXH2qxaNeSvzAfSpeqNVdGPa7nIcnjsK1ba2/eKQcfSuf0y53sA55FdBHcqiDkUkla45VXaxox2/zjLZp2p2CTwLlc+vei1lDFSTmtpAroAcc1jWjdM5noN8IXE2lkwO+bd+Vz2PNejeeHtkJOCehFecarJHDp77CA6DI5rc8J67Ff6aFaQMycDnv+ddWCk0uRnmYiOvMdxEP3Q561FLaxSEFgBz1pdOmSaBQCCRV024xknJ+tegcbZ4n8S9Fey1AXMfzRuBkgfSsnw1b878df/rV6n4+s1utImwMlVz/KuA0aHy41B4xx/KnBe9czm9Ct45jVvDc4xkgDFfKPiM5u1BOSFr6y8ZK82g3KxjPHavkbXWLalKD/AA4Wrk9Qpoz6KKKg2O3+D9j9u8a2wxwiM36V9h2qhIlHoP618zfs62Ak1u5u2XhF2A/ga+mofudO1bwWhyVXeTHt1ppOP60J8zYpZRgbR3qiBLNTJMWI46VrqcDjtVO2VY48Y5p7S4J5oQy0Hx1o80Ec5qkZT6/Sk35HXii4F3eMdaQyL+NVg3HWkJJ6UXAsGTnvSiUYqpkn2o5ouIu+byAKkhclsVRRWJwAavQt5S5frSuM2babycc1oNJHPFwea54zkjAPNSQ3RBwCcUCszS+zr6D8qKq/aG/vH/P40VpYLnzaAKeKAPQU7HT+lcdtDoFD7E5Hemm8LIeSMd6XGRg1Sntn5Ccg9jXJiaUpe9E9XLsVTp+5PQhubvI5c/nWfJqHGEJJ9adPaXLNxGD74qNdHuZD8zJGv+zwa5VQnPoew8dQpr4iFr8IpDEMx7ZpdP8AtEzMQh29s1r2mk20AyyiR/VuavqoQYUBR6Cuing0tZM87EZxfSmjMRLpACFXP1qyk1xs/eLz6CrWaM8+1a/V4LY4nmFV6uxSivbiIn9wCKu2t9G4/fRbCfSlyaaVVjyBS+rrozSOYyT1RfhltQ24ybfqaS41O2jOEcH8aypbRHPTinLZ2ykbkyfeuWdGcXojvpYyjU1bHz6v5h2RBjmtCwbcMuc5quIbdUyi/N7VJAdpFRyOL946lVjNe6Z2rWT2V0J4cmJzz7GmC8dnQA8HvW7NKrKVYBlI6GufuoFjl8yJvlB5Wm9NDFt7nSaddnaAeTxWxHfOiZJ+lcRaXirgb+a1VuzKAsZzmiUU0ZJ33Lup3s1wxVc8joKyPC+qT6HrIt7nPkzN8rZPHIrUto9rZY81n+JbRrq2JjRgy8g+hpRTh7y3FU5ZLk6Hr2j6rujRlcjIB/lXSW+oOxzvyPevmHRvGF1o0ottT3FFOA4//V7V2J+I2nwQbvtSMD2B5/lXZGvCSueXOhOLtY9T8U6nDb2UyyMGLrj+VcdYYeMshyDyMV5zceKX1242ws4i6fN/+qt7S57i2UGOQ7fQ9KI4lKW2gSwcpRv1O0kthcW7xMPlcYNfLXxW8I3Hh/W5ZypNrN8wbjg8cfrX0zpWtRyMI5xsb17VY8S+HrHxLpbWt1GkkbjAY9uR7j0rthONVe6zilGVJ+8j4gorrPH3gy+8J6k6TIWtGb93KOn061zlhbNdXUcSjO5gD7DNS4tOzNlJNXPoH4BWQs9GMzD5pju6V7dEcxDHpXl3w+jW00+CIDGFH8q9LtX3Q9ea6Fpocb11LFqwLHNWQm59zdqoW0beaWJwKts5bgdKSEyWSUDgUxfmpI4ix5qykPQYqgIQnNTLHkjNTLDjtQUbPyj8aAFSEH6Upi7Cnw5zgirsUOe3ahBczhbknjrVmOyyea0EgA9M1dt4AoycU9hXKcGnD0AxT300NWrERjmnlgalsLmENP2jHX2p62ee3NaxK/jTSy800FzO+x+5/Oir+9PUUUxHy/mlzjr9KYKdXJdo6rC/jRnH+NJzjijNK7CwE4//AF0hz6mgmkouMO/A5pMcUHrUkcEsp+RCaTly7jinJ2SI+3Page3NaMGkyEBpTj2xU32FFHArnnilHbU7aWX1Km+hkUoVj0BrRS2UvhR8wq9a2wbggHHtWbxTeyN/7MkviZjJayt2x3qZdPkbqcfhW6bM9scVC0flsVY571Eq9Q2p4Cl1MG9tZLdRJuHy9aWKXzEDKOtWNUJaMqOnSq5ga3gVox1HIrPmk3ds6o0o0VaKEuH2pz1rAvp8BsHtWjdzHYc5zXO3shORUTfY1ir7mfPevFLuXkitrRNajcgBgJPTNczdLnJxWPcF4pfMiJVh70RbRFSCPbtN1NCP3hXmtfzobiEgYxXjmh695iBblyrA8HOc9feu00/UmfaAwK+uf/r1tzNaHHKA7xH4eS8DMFBOPTPrXA3HhiZJSFjJH+7/APWr1iK5GwdGzVlIkmGSi/kKzlDrew4VXHzOI8OaG8CoGBHPpXf2do0URDDPHpU1pCisCFA+grRiAGQVGKlKxUpc25hXMG6TKfKauafqd1pxHO9P7pqzdRq7HAxWfcRsoLDkelCnKOqJlTjUVpI2NWtNI8Z6VLZXqDeykbS3IPPvXhOs/D9/CWvAKHktWb5X64GfXHtXqmOjKSreoNOubt7qD7NdKJkHQkc120semrVDzquBkvgKWgLsRNvYf0r0HSSZIxxwOprk9GtbZ5kiV/L9Qa9GsLJY4lEeCvtXoQmqmsWefOEoO0lYiVC3Cg4q1BakjmrsVsBjIq2iqoxgVol3M7lWK2wOAaspbjpUu9QM0huFXvxVCAQKB0qYQLVU3KgckVBJfomRvoug1NHZEOeM0GVV44FYkuprn72Px/8Ar02K+Vzknik5dh2OgjlHUjmnNcgDg8fWsR9SiVcbhVC51mNchW/X/wCvUuRSR0rX4XuM/Won1RV5LL+dcNc6yWJCk/n/APXqjJfTSdC35mp5g5Tup9ejTncKzbnxPgHaQfpXLJDcXDDhjn3NadnoE8uC4/z+VHM2OyLf/CTv/d/Sipv+EbHr/P8AwoovMWh4znFKuSemacqFmAAOa2rOzWOMMeSa5KlXkVup6GFwssRLTYyo7WR/YHip005iQCw/OtCRkU4AOareb84x19K5JV6jPbhlNJLXUhl04ryD+dJBaRuSGyDV55spnPTrVSOXZOGOMZxWbqTvuaRwdGO8USCyhjYZ5PvV2Laq/KBioriSNznNVZrtEHGamV76u5pCjTivdVjTEpAOfzqOCeNnZXIzjisaTU0IwOtZcuoAT8Uc6Rap30Opt5IkvDkjBq69xCnMeOa88l1M/a1G7vWlHfknjn1o59C3RvudS19xx1rPnu/3oLVkG8yPSql1ehULZ5qee2ovZJF/UJQWXnqauzt8iAHtXMQ3JurqBB681tyFsjOeBgU4yvciUbJFTUvukjr3rmLvvj8q6W7STNYF1A7MdowamoTTMiTLggdax76BsMMVsSBoLg7qe8PnKTTTM56M52xXnawwQa6TTJJIZFCOcVky25jlJHWrNpc7XAfIPrVyXMrnOpcsrM9D0q4BKGQhlrq7ee32cKPrXmWnythTG5De/Q10VjfMpAlUr+HFCk2rEygr3R2qzKF+Qc+1OWWVsDGPrWLbahGAMkA1ciuvOPyEt/Oly9yW0amRtOSKgIEmQaW3t5ZD9whferJiSNdpIzUNMXOkYs0ZRiB931ppiyu5eorSkUNlV5qPy8cdqzkuxopoyUWQsSRgdjW5o/iC709lVmMkWcEGqgjJJAxio54uOMVFOpOk+ZMVWnCqrNHoEHiCGeMMpx60ja6ueCMV53BI0MgP8PeuhgtBcRB0OQwr3cLivbx80eJicM6L8jfbXgBjcKgl18kcHp71lf2Y1KumetdOpy2Rak1qRs4b9aqtfzv3apY7BQRxV2CzjIA6Gh3GUEeVuWJNOa4nVcIDWk2nycmM8UJYS98UrMdzFkmuG6k/hTVhmlPciupt9KJOW5Nalvpip0XmmoNickcja6RJIRkHFbVnoKggsMmujht1XgDip1AWqUEiXIoWumwxKMIKvIioBgAUpI9aY8gH5VZO5Lke9FVftC/3xRRcLHz/AG5AbNX2vNmBjisouRyDyOlRTXm0ZcdK8fExd79D6bKqkVFw6mw8qsd8RG7uDVRpG35GM1jTX64+Q4/GoftxJ2qx571zN9D3FI2Z5GKnD9qpPdmOMDdWfJe7Bg4596o3l0cDHNQ79DOUk3qdKLzMHLCqVzOChy4FZK3vlwZbrjuax7rXIkcmRhx2B/8Ar03q7GXtLbM32l5yOapSEvOCxwPrXOS+K4VbhSwH+fWqU/i0k5jtix9MmqVJi9t1Z1v7syD5stmtCGUIoGR+JrgbTUdZuX329kxz9avMniecACF4vpmn7Mft21Y62a629WUfiKxdW1m3tUPmSjnsOapW/hPxBe4M9zIufUGtvTfh1FGRJfzNM2eQRj+lHsb6kSrsseB915vvSCIuik9+ldiNh56msaKIWCLb2yhIxwAKuQM52lqduXRGTcpO8i1PFvB7YrMkiXcxxwB1q/NPtG0dTURhJTaOp60m7sLWWpzk+nC4dpGX6UgsvKjyBXUR2YdSB0FN+wAp0/SnGmYyqNnINZq8y5XGar32khTuVSO+a7CbTMAMo6c9Kp3cDlQuMUcjW5m3zPQ53TSYLgRy8LnANdpaqiqCwUr9K5+Sy74y1aWl3USjyrg/MvrRD3XqEtrGuJLUMN2MfStuwv7aJcRqo+orA3WR+Ykce9TJPaI3ykY+ta/Mxa6HSNqpbhOT2ApiR3Fwd058pPes231KKFf3agk9qk+0TTktI/lx+metQ6fzIvY1iYo4ysfPqfWoW6ZI5PaqUdwA4EStIauKOA9y4TuFzWbjfVDjKxKkSgc8NUFygUH1pwl8+XEZp11hYvmPNYuPSxqpFJlDKRjpVjQ9TaxuPJuD+5J4PpVS1Yndk89jTJoi3JPPrWUKkqUlKJrOnGrHlkehwFJkDxMGQ85Bp4hyeO9cBpmsXOms23MkZ6qTXZaNrttqP3tsT9wTXvUMbTraN2Z4VfCTpPujWttN80/KOatNo0pAIUj6VNbShNrxlSvqDmty2uVkTBwDXYlc5W2jCh06ePjBIq9Dad3GDWmzqRnj1qAuAT6VSjYnmEWFVGMUEY6U15QB1qJpfSmA9jgVGXx1NQyT/nVeScDuAPrSuFiw8w/yapX11siO3rjiq9zched1Vg4nYAt1qW2UkVft8n+c0Vp/2eP7w/KilZlXPDzjNRuiuPmXOadnPakPt19K5mk1qbRbTuilJYRN0O36VG1giKTvZQOta6Wc0gyFwKr3WmTzAoxIU9cda55+yWyuelSWLn1aRxetX1tbvtiLSMO9YbazOxxFAD6Zr0FvC8eRuUnPf/JoHh63t5gQuQf8+tcdpp3asevCEOW0m2zzp/7XveCzKp7A1YsfC01wwNw/J9//AK9ejyadFH90EfjTQqRjinZ9WWlFL3UcvB4Qs0RTIgY+/etSPRdPtwpaGMA+1XrmZipC96alqZFVp3wuaHK+kSowsryZsaTPYQoqpDGT0zir8t5bHhYk/KsaGK3QYTNWDaROAwdgfrWjlOxi4Uk7l5tSijjwAo+grLuNQZ3AQ8GlmSCEZJ3EevNYWp34U5RQMdgKzlJ21Yo8jfuo0EnEt6FY5FXJv3SjB+lcj4fvnvdUZdu3b7V2FrbtcTB5M7Rjiou2tBuylqSWNu0v72Uce9WyAXCRqOetWZeYwiZz6VNBBHbx7mbLdafLbQnnvqJ5SxgE4pkZDgkDg1DP5lw5EY+X1qzaRhY9rcsKpNvUyaSWpOturIQf1qhc2qlDx+NXlZiQuOKLnci7SOtaNsy5dTAe0AYjFYmpWBUmRc7ga61uWPX61RvYQ4IPQ1m9S2mjnbBHnIU4J6c1swadEOZUIP0rLEbW9wDyOcg1rwXVztGYxIOxAzVQ22Mam5OiLGf3ZwasIUUbpt0renWollkY825H4VOsroBlY0H+0K09TBlmK4vJcJbQ+WDxyMYq9DpDsvmX1yc/3VORWcdWWJP3bb2x/BWfdajdT53nap7d6zly+pSizelu7W0ylvl5OnSo5JhIm6Vhuxwtc7GZ+sURHqz9atwJJt3TGokm90PToy7DPiQ5GRUskm8nBqiZo04BBNM88tkIPxrklCz1OiEixGyFyC3enyAbuCR24qrawEtuc8npV3ysygLzniubXob2T3JrbVdSsSPJuX2f3SeK6XRvGuWCXoZWHBYVzFwoDDOOKgliWQHjGa7KGMqU3a5y1cHTqdD2Cy1eK5jDxSb1x2qz9tBH614tYX9zpc4MRymeVNdxpOv218Mbgkn90/8A6q9rD42NbR6M8evg5Un3R1xuhj5T+tRvcgjrWS3mYzGMjtUDzSoDvUiuu5y2NSW4Hes+5uSOmagWYMeavWkSz8YyPek5LqNJsy/tAdvmPJp4inX95Ec98VrXOixspYEg/Ws/7Jc2rblJZM80k7js0Q/b7/8Aumirf2tv7jflRRyoR48iNI2F61tabp6AbnwW96x7OXy5eehrVF2VIOeK4K8mtOh7eW0oybk9zSktwOFcAelUJT5SFmPIoW9UnJNZ2oXWWLFvlrm6XR7q00ZYNyxBJ4FULu7RhgEZrPn1FipUMABWV9tYy8ZNZymkJwRu+cHXB5P1qvdPHEfmbk1Qjadz8vAPf0qVLVQcysWNXClOocVbGU6XUHvEVSQMntUX2uRkIAJPYVaWGIdEFPAA6KBW6wr6s4pZn2iUbeS5UECM/nVxJLnks2PaiSRY1JJ/ACqC3lzLJshiwPU03ClT0kyFiMRX+BGjsZjl33UxoITyygn6VesNLubkAyM2DzjFbtnoMEQzIu4+9LnppaII0q8n70rHMWllGkqyRRbCe4GM1tI5iQLjtVy7iSLhVGB6VCFEhG7gVjKXMdsKDppdRYbhI1yx+c0+GGa7kDMCEFKlvCG+dsj6VcR0VcItYtdzoS00JFEUCYYjikhMZyV61SuZ+Dgc0tm5Kjk5NNSvoS4K1ycvtkIUZolMz4JQ4rRsoUXkj5jVqWBNnFNN2JmomDJEcAsODUDxD14radAchgKzbiIqTwcVVyEzC1GyZ1JTnjtWXDeS2rFWBxXRyhkYY+70NRS6UlyDIq4am01sS1GS1MZ9VeQbU3Z/GlQSu24h/wAWq3JbGB9jIQfXFW7fToXQM5PWqi7s5pw5VoUvOaAcKCfpU0QvZxuCCMdiRmrn2O3gO4Lk0rynAC8Y6U35kcra0Khtb/HMyAdPu0kdnck/PLn+tEjzHhiwHqKlg3AcNk0uVMai0OFidwUtitCK3VECoATVVXkHJHNTw3IiH7wYJ6Co5UVaRakRY05GW68VJZJhtzD5iKqQuZpMt0FaSbsk9gOK5Z00/eW5qpSSsMmh3jnH0qERqHOD0qOWSVpTj8KnX5Yct941hyrc0UmZt0uZM/pVeSE/eQlGB6jitCWLPIqFkBYCkm1qjV2krMvaP4ouLRkgu2JiHG70/Wu1sdStruINDIsg7j/JrzGeJTvwMEc1FBcT25D2kjRsOvJr0MPjpw0lqjzsRgYy1joeqXKR7d8ZxmtPTRsiX6ZNebad4mne4SK7BIJ616dpyK9urIcgiuydeNX4Ti9jKlpI0IW3DHWmTiRIpPKAJK8Ci3XEq1baMHoc560Qk46olpPc5PZqP/PNfyorqvJ/2RRW31mRPJHsfN5Pp+lPEjMOv4VFn3ppanOmprU0oYidCV4jZJpUyADVSZbifg4A+tXCx9aaWOcZrJYaPVnbLNKjWiKi2YH+sbNTJDGh+VRTycentTSea0jShHZHJUxVWr8THZ4oOc4ppNKivIwApzqRgtSaNCdZ2igzwPepooZJB8oq3aacd43Dg+tdBb2sUSAnHFYurKW2h6FPARh8buY1hoTzDfJ0q2bKG2ZS2CR2NaUs0hG2P5R7VTkiUyZlfr2NYWtsehGCS12LdreLGAqAYq07Fo92QCe1YnmRQyEZFEt8p6MMYrN36ibjHYW+fbkjrVRbrDYIGTTLu7jdCFPPrmstmJ53+4qo05N6ETxUErNnQxzo2ARg+1W2kRk+TOBWBDcoUPIBHrWhBeIIxuxgd6HTcWZwrxlqmWAoKFiDU1moIWqck/mL8vC1ZsnDEGoaubcxvQbRjNWsgrgDjFZ8Mg9c1filXGc07WJcrogKAtz1qOWHefY1YmdScrio2fjIxxTWhNrmFc2kq3IjYgp1HNadrAoTB7UM3mHd3FKkyrwOafNzMjkcFYmmsUlTIALCqEtmo+5wfStGObbyCKrXUg8zK/jTvcmxkTREEhjiqM2QcDoK1bpt55qrMibeMZ9aFdkuyKAuDnZQhZWzUM4xKBmpo3xKEPek5MuPKXUfgbqkWITMBgGoWhLnbGamiV7bAbNZtv5GkbFk7YlCr+dWopB5PB61QZ1bGTzVqNgq5PAFZNvcbgraEhQKn+0aR4mwOuO9ToocA45NSzKQoXpgVlKKlsLbQqFAFNVJYzjcKvgZBHOBTShwRjis3EtaGXKMwnK/Me9VTEUAHXNbJj3soVeBUc0K5B4zntQk1qJlK3iVx0wwr0zwXd+fpgRjlk4zXnjQlG3x9D1rb8Gah9k1PyHOEkx+fFdFKXJNNnJiYc0broekr/rAangc7yMVXi+Zgfb+lWbY8kmvQPOLO4+1FJu9hRTt5gfMOfXpSMfXg00tSE12WOa4p603gUhPNIT6Uigo70gVmOBkitK0s/mBkHFZVavJotzrwmGdeW+iILa0afHUfhWpb6eIxyeavRrGEAQDimmVIj5kp+grmsvike9Cn7NctNWIw+OAOlCXZZsM3FUNQvSzHadqntWYbsmYBM+5rN1LlySirs6aSdYk3bh7Vj3t6ZB8p59c1SmuWYYLEmq5ck1tGnKXkjy6uNjDRask3yFt0jUplOPl6VFnjmk3HtXRGnGPQ86pialTqPLE85zSFu1Nzj3/ABpCT61exhcC3PHFAmdOFY0xm5PpTGbmla402ti2uoSKm1xu+nFaWm6lF5QQth/c1zrEZ61EW5JB/Ws5U43vY2jiKi0udr9udeQR+BqWHU5AQHPBrhlvJ4z8shrR02+muH2OMr61m6Kex0RxdtzsxqfuCPXNWP7RVo8jFcmZCCV3mlhuJEbjLr7c1lKjJdDphi4S3OsilG3p1680xnAkx29ay7a9VlUZK9ueKla5X1rJxsdfOpbF+SQqoKnmiN9x5NZn2oMcFuaf52ehoViHsW5wCcmqkpVVPNRzXuF+Y1l3t8CDtIp8xm0PkPm3QGemelPIbf8AKRke1ZljO32nzZOh9a1yUbMmenNEbNGc9yzbTbDufggVNBfb5tkmMHvWaZ1lULjn1qFkkRg0bnIqJJ9EXF23OpNmkozCeazrh5reQKVOAai0zUGhbEjEGttJ7e5+9gk+tRa/kWp9Rtjdh0yOD71cEik5Y5as6ezYEmCoI5mhcrNn61lJOLLTUjW3D6VMqKFOeSe1Z6XCuCcipIbjBySPYZp7oGXPIGTtOCearyxleMZ96sQyMWDEg5pLnlutLl0BbmeV3KwHWod5tZI5R95WB/UVfCbCSR1FVb1VZT+dQ1YVr6HqOlzi4soZB3UfyFadt9wmuQ8F3Xm6YqEklOOfwrroP9X17Zr0acuaKZ4848smibPv+lFMyKKu5J8wk/hSbgO9R7vekLcZrtuYD8/SiPDzKpOATjNRk+5pCf0oA76x0KMWQeNSxIzmsi6V4n2EYx60eHvGE+kwGGaIzx8Y45FU9a8Q/wBozb44REPccmuerR5vhZ24TF+xeuwsl00edp5qhLO8r9zULXbMOVzUTTs3QAD2rL6tJ9dD0Xm0EtFqTTNxhz+AqvnGAvAppJx159aM9/wrohRjDbc8qvjKlZ6vQdmjPrmmg80Bs81rY5h2eKXINMz6Ckz+FILj8/SmE9qM8+9NJwKYCsfeomYUpPPNRM1KWg0DHJxULninO3FQM3rUFIGbniug0W32x7iOTzWDaxma4VR0zXZW0YjjAB7VpTjd3IqOysUbtcPyKj02fyL9cgFW/wDr1LenMhHaqs0TbA4B4q3uZ9D0i106zvYVZkAJ7rTLnw9buAsckinnn/JrO8N3kqQIeo//AF10gnBUu3FOUIy3Rcas47M5C+0MWkgPmsxPqaF0O6dMpIu361c1+/jdwinJB9au2E5+zg1n9Xp7WNVi6vcwJ9AuccyjP1rOu/D9wqb9wYDkgH/69dhLMSTyc0kTFmwe/FJ4an0QfW6nc87kbD+UBgg85qaW6EcWzJyeK9ButAtb2LJTZIf4hxXOah4SuoSWhxIo56c1yzw8o6rU6qeKi9GYcdwUt845qxbyPIFBOSaqTxSRyiOSNlAPORV63kVACFGcd6x2N077FqW3ZgGXIx601XlUjyz847GprW5B5fmrTRpKuVG0+tTaMtSrtEulawE/d3JUN0wa1XS3u0ypzmuXurOOUHJAk9aWwkmsnG9sr2FZuLXoapqWvU157dostHkqO1RF9+GVsEdRV22vo5oxxz3plzZRSKXiOGx2pcieqGpNaMms7gEDcfxq2HD8noPSubt5TbzGKfIAPBrWWdeNh4I6VElc0T6FuWXBwMH61E7IzAE8+lQtKM5NMaZSeB+NZPQ15dDo/B04ju3g7N0H5V6HHxGoz2ryjw3PjXIQO/X9K9VT7qjrwK6sI/da7Hk4uNqhJ+P60UnP92iuqxzWZ8sbuMZo3H1qENnvzRu4rsOcm3HHWkznoai3Uu6gCTIozUeelG6i4EmeaXP5VGDk0uaNQHZo+lNBxnrSZ/GgB/SjvTc+1JnsDQA/nFJnikz60hagY4nANMJxQT+dNZqWoIRjxUTNinMepqFm96m7KEY89ahY+vanM3pUTc4FFnbUZsaBBulLnseP1rqSv7vcPSsrQ4NltnHXnP51psxWNhXRBWRhN3ZmygyXOMZycGtKe0Bt+naoLRQ9yM8nPWtK+kEcYoATRTJafKx+Spdb19IU8uJhk5HX/wCvXP6hqRiibBxxxXKz3zT3HLEnPrRayFc6mK4a4kDuSSTXUWU4W3WuGtZwkanPStEawioBnGKaFc6hpcnOcVZs51Vgc4riY9YM0u1SdtdNpy+fDuVjupoG7nY2V/C+FOBj3q67xleMGuI/fW7Z5NXbXVcEK+aB3NTU9Ls9QTbLEN3YjiuQ1bw/NYAyRndDnn/OK7GG6DDIPFQ6qhurJouOaxq0oyTujWlVlB6HBw/K3WtBJyVC9vWoLjS7u1fcE3RUQXEWdpG09815drHqxmpF2O2MpB7inT2wcbXGGFOtLmNThWXHrkVblngbhWDP60bGqTZjG3mtXDRZI9K0bfUm27JIiDVmDYpG5k+hYVaMNtL8wK/mKGl0Kt3My+RZofMZQGHPFUIbgLJt5H1rZmhCqdrjH1rJuo15YOF46ZFYzuy0rFtW3Dk9aQsFyazba4LEIG3N04Iq49lqc6/6PbyNn1Fc9zXmstWXfC8vmeKLdVOeuf0r2SP+HPoK8v8Ah74cvbfVTeagoXb91c+uK9QThQa7MJFqLueXipqc/dJt1FR5orqOax8oZ5pc1ot4d1gH/jzkx9KcPDesEf8AHpJ+X/1q6rNnNzx7mYG9sUoJ9BWmvhnWT/y6Sce1SDwtrR5+yt+VOzFzxMnOenanA+1aw8Ka3/z6v+VSr4Q1sgf6Ow/4DRysfPExQelAOenH0ra/4RDXP+eBx/u0h8Ia72gP/fNCTFzxMbNLn0zWx/wh+u4z5WP+A0weEdeJ/wBVg/7tCTDnRlZ5oH41r/8ACH64QcqPf5aVfBWtMBkqPqtVYOdGP168Uhz2rcHgfWD1kX/vmmnwPrH/AD1T/vk0rMOdGJk9MGmGt0eBdWPWdB/wGkPgPU+f9ITP+6aXLIfOuxzzHHvUb+tdH/wgOpE/NcoPwNO/4V9enrdp+RpcjBT8jlG6dRmn2Mfm3Kj3rqh8PJ/4rscfWnx+AJ4X3JeKD+NCi7j9p5Fq22pCAMVFeSBVwDUv/CIXoH/H8v5GopfBV5IOb5fyNb8yMtew7S2G4sxGai1e9QAAuOKfH4Iu1HF+OfrTJPh9LMf3l7/OpQXfY4nW9UX5huHPpWJDeDfnIxXpb/CuGT790SfqaVfhLbdrrH4mqT7i17HBLqoSHlh0/wA9qozaxubG8f5/CvTf+FRW7D/j6/U03/hTVsT/AMfXP1NNMV5PocJpupLGQ5YHHJrorHxVBARmVV/z9K3h8HogvF5x9TUbfBeJ/wDl85/GmTr2Kz+NbVlx5qk+3/6qjj8Rwynhxj/PtUknwQIGY7zFVX+DmqRZMF2Dj2NO/kF32Om0zXI3xmQfj/8AqrprC/hmdBuBFeax+AvEVj1/eL7LVq3tdZ02RXlt5Dt6gD/63tWctVY0jKzPZoxaSphyD7VZj0HSbmPBtlBI+9jn+dcf4Z1SK8QLcIYZBwdw/wDrV2tvcW8EYLTqVrz5JdTsTvqig3gHTpnyksqA9lOP61KPh7ZoRtuJEHqx/wDr1pRavLIcWcWf9s8irkbO7Brmbc57KcCsuSD2Rp7Sa6lW18E6OiDzZZHPr/k1O3hnR4uI0lY/5960InBAHYVMHwAABmhU4roLnl3MOXwzYzf8sivpx/8AXqBfBOmF90gcj0/ya6dSq5LHLU8NuAqlTj1Q/aS7mJB4d0m0IMFhE7+rL/8AXq7JGIlwiLGf7q1cZgn1NRcM2T1qlFR2RLbe5UiixyanA7VKBxSqoJzVLRCItnsKKlop2RPMVjBEcZij/wC+BTTDH/zzT/vkUUV6xwjGhjAyI0/75FN8tP7if98iiigCNlUHhF/75FMcD+6v5UUUhjCB/dX8qYQP7q/lRRSGRvgnoPyqtJgjOB+VFFLoLqV36cAVA5NFFLoUiNutRk0UVD2GR0GiigBrdaYaKKQxhpp5HNFFNgMP9aTHNFFIYoFSL1oopgSqO341InUUUUuomSqeakUmiiqQiUdBTgTmiitBEiE1KGPFFFCJHg89AfwpPLSTho0P/ARRRTBDP7PtnJzCg+igVy2oQrbXuIiwGehYmiiufEpcptRfvGxY3EgUAHA4rTgnkJGW60UVws6TatCQo5qYuwPXrRRSAnj54NSLxRRTYA/QU3tRRVIQnXrQrHNFFCEPzRRRTEf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The examiner supports the patient's arm with one hand, and asks the patient to extend the thumb against resistance applied by the opposite hand of the examiner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Finkelstein test for de Quervain's tenosynovitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The examiner gently rotates the patient's wrist ulnarly (arrow) while the patient's fingers are folded over the thumb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Sheon, RP, Moskowitz, RW, Goldberg, VM, Soft Tissue Rheumatic Pain: Recognition, Management, Prevention. 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7303=[""].join("\n");
var outline_f7_8_7303=null;
var title_f7_8_7304="Pathogenesis of pulmonary hypertension";
var content_f7_8_7304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of pulmonary hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7304/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7304/contributors\">",
"     Lewis J Rubin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7304/contributors\">",
"     William Hopkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7304/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7304/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7304/contributors\">",
"     Andrew Nicholson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7304/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/8/7304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension (PH) is a disease characterized by elevated pulmonary artery pressure, which often results in right ventricular failure. It may be idiopathic, familial, or associated with multiple other diseases. PH occurs in men and women of any race or age. It was previously considered either primary or secondary, but this classification is no longer adequate. The revised World Health Organization (WHO) classification system, from the 4",
"    <sup>",
"     th",
"    </sup>",
"    World Symposium on Pulmonary Hypertension, is now used to characterize and classify patients with PH, as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of PH is described in this review. The definition, classification, epidemiology, etiology, clinical manifestations, diagnosis, treatment, and prognosis of PH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The revised WHO classification system includes five groups [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients in the first group are considered to have pulmonary arterial hypertension (PAH), whereas patients in the remaining four groups are considered to have pulmonary hypertension (PH) (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). When all five groups are discussed collectively, PH is generally used. We adhere to this nomenclature in the discussion that follows. The WHO classification system is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEMODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By consensus opinion, a normal pulmonary artery pressure is defined as a mean pressure at rest &le;20 mmHg, while pulmonary hypertension is defined as a mean pulmonary artery pressure &ge;25 mmHg at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/2\">",
"     2",
"    </a>",
"    ]. Many clinicians consider a mean pulmonary artery pressure of 21 to 24 mmHg as borderline elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/3\">",
"     3",
"    </a>",
"    ]. The definition of pulmonary hypertension is no longer based upon the systolic pulmonary artery pressure or exercise derived values.",
"   </p>",
"   <p>",
"    Hemodynamic variables that contribute to pulmonary arterial pressure can be identified using a variation of Ohm's Law,",
"   </p>",
"   <p>",
"    &nbsp;Change in pressure &nbsp;= &nbsp;flow &nbsp;x &nbsp;resistance",
"   </p>",
"   <p>",
"    Ppa - Ppv &nbsp;= &nbsp;Q &nbsp;x &nbsp;PVR",
"   </p>",
"   <p>",
"    &nbsp;Ppa &nbsp; = &nbsp; (Q &nbsp;x &nbsp;PVR) &nbsp;+ &nbsp;Ppv",
"   </p>",
"   <p>",
"    where Ppa is mean pulmonary arterial pressure, Ppv is mean pulmonary venous pressure, Q is right-sided cardiac output, and PVR is pulmonary vascular resistance. The Ppv is estimated by the pulmonary capillary wedge pressure (PCWP),",
"   </p>",
"   <p>",
"    Ppa &nbsp;= &nbsp;(Q x PVR) + PCWP",
"   </p>",
"   <p>",
"    From this equation, it is apparent that the mean pulmonary arterial pressure is determined by the pulmonary vascular resistance, right-sided cardiac output, and mean pulmonary venous pressure.",
"   </p>",
"   <p>",
"    The primary cause of significant PH is almost always increased pulmonary vascular resistance. Increased flow alone does not usually cause significant pulmonary hypertension because the pulmonary vascular bed vasodilates and recruits vessels in response to increased flow, so that little, if any, increased pressure results. Similarly, increased pulmonary venous pressure alone does not usually cause significant PH. However, a chronic increase of both increased flow and increased pulmonary venous pressure can increase pulmonary vascular resistance.",
"   </p>",
"   <p>",
"    Pulmonary vascular resistance, flow, and pulmonary venous pressure can be altered by numerous medical conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased pulmonary vascular resistance may be due to conditions associated with occlusive vasculopathy of the small pulmonary arteries and arterioles (eg, idiopathic PAH, connective tissue disease, HIV infection, and congenital heart disease), conditions that decrease the area of the pulmonary vascular bed (eg, pulmonary emboli, interstitial lung disease), or conditions that induce hypoxic vasoconstriction (eg, hypoventilation syndromes and parenchymal lung disease).",
"     </li>",
"     <li>",
"      Increased flow through the pulmonary vasculature may be due to congenital heart defects with left-to-right shunt (eg, atrial septal defects, ventricular septal defects, patent ductus arteriosus) or liver cirrhosis.",
"     </li>",
"     <li>",
"      Increased pulmonary venous pressure may be due to mitral valve disease, left ventricular systolic or diastolic dysfunction, constrictive pericarditis, restrictive cardiomyopathy or pulmonary venous obstruction (eg, pulmonary veno-occlusive disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the cause of PH, a predictable sequence of events occurs. The right ventricle hypertrophies in response to the pressure. If severe enough, the right ventricle dilates and cardiac output falls. By this time, patients may have severe symptoms, including symptoms at rest. The exceptions are those patients with a congenital cardiac defect and Eisenmenger syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MOLECULAR MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the work described in this section has been performed in patients with idiopathic PAH (IPAH). It is unknown how applicable these mechanisms are to most other types of PAH or PH.",
"   </p>",
"   <p>",
"    PAH is a proliferative vasculopathy, characterized by vasoconstriction, cell proliferation, fibrosis, and thrombosis. Pathologic findings include intimal hyperplasia and fibrosis, medial hypertrophy, and in situ thrombi of the small pulmonary arteries and arterioles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The pathologic appearance of the small pulmonary arteries and arterioles is qualitatively similar in all patients with group 1 PAH.",
"   </p>",
"   <p>",
"    Pathologic classification of the pulmonary vascular abnormalities (Heath and Edwards classification) was first done using patients with congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/9\">",
"     9",
"    </a>",
"    ]. Grade I and II changes are characterized by muscularization of the small pulmonary arterioles, followed by medial hypertrophy and intimal hyperplasia (",
"    <a class=\"graphic graphic_picture graphicRef64141 \" href=\"UTD.htm?12/62/13283\">",
"     picture 1",
"    </a>",
"    ). Grade III abnormalities are characterized by collagenous replacement of intimal cells, leading to an \"onion-skin\" appearance. Grade IV through VI abnormalities overlap and can be considered one stage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. These changes are irreversible and associated with a poor outcome after repair of a congenital shunt lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the proliferative nature of PAH, it is considered by some to be analogous to cancer and a multiple hit hypothesis has emerged. In other words, patients with PAH may have an underlying genetic predisposition to pulmonary vascular disease and a superimposed second hit activates the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The process may involve increased endothelin levels (endothelin is a vasoconstrictor and mitogen), decreased nitric oxide levels (nitric oxide is a vasodilator and is antiproliferative),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased prostacyclin levels (prostacyclin is a vasodilator, is antiproliferative, and inhibits platelet function) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/7,18-23\">",
"     7,18-23",
"    </a>",
"    ]. Advanced therapies have emerged that inhibit endothelin, promote nitric oxide activity, and replace prostacyclin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Advanced therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predisposition to pulmonary vascular disease may be related to genetic mutations in the bone morphogenetic protein receptor type II (BMPR2), activin-like kinase type 1,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    5-hydroxytryptamine (serotonin) transporter (5HTT) genes.",
"   </p>",
"   <p>",
"    BMPR2 is a member of the transforming growth factor beta family. Abnormal BMPR2 may play an important role in the pathogenesis of IPAH, with up to 25 percent of patients with IPAH having abnormal BMPR2 structure or function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. The BMPR2 pathway induces apoptosis in some types of cells and it has been hypothesized that abnormal pathway activity may permit excess endothelial cell growth and proliferation in response to a variety of injuries (",
"    <a class=\"graphic graphic_figure graphicRef82031 \" href=\"UTD.htm?25/47/26352\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/28\">",
"     28",
"    </a>",
"    ]. This is supported by several observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transgenic mice with smooth muscle specific deletion of BMPR2 have pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endothelial cell proliferation within plexiform lesions of patients with IPAH tends to be monoclonal, consistent with an inability to normally terminate the proliferative response to injury [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The activin-like kinase type 1 receptor is another member of the transforming growth factor beta family. Mutations have been identified in some patients with hereditary hemorrhagic telangiectasia and PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    5HTT activity is related to pulmonary artery smooth muscle hypertrophy. The L-allelic variant of the 5HTT gene promoter is associated with increased activity of 5HTT and is found in a greater percentage of patients with idiopathic PAH compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     PAH second hits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second hit that activates PAH may be another genetic disorder, increased flow secondary to a congenital left-to-right shunt, an infectious organism such as human herpes virus-8 (HHV-8) or human immunodeficiency virus (HIV), altered structure or function of a membrane ion channel, drugs (anorexigens), inflammatory mediators, or cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with congenital heart disease, left-to-right intracardiac shunting increases flow through the pulmonary vasculature, which causes shear forces that disrupt the vascular endothelium and activate cellular mechanisms critical to the pathogenesis and progression of PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/2,34\">",
"     2,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of damage to the pulmonary vasculature differs in patients with atrial septal defects (ASD) compared to ventricular septal defects (VSD). Vascular injury is related to the degree and duration of volume overload alone with an ASD (",
"    <a class=\"graphic graphic_figure graphicRef72533 \" href=\"UTD.htm?23/17/23826\">",
"     figure 2",
"    </a>",
"    ), whereas high pressure shear forces also contribute with a VSD (",
"    <a class=\"graphic graphic_figure graphicRef52487 \" href=\"UTD.htm?12/0/12290\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with an ASD, shunting is delayed until maturation of the pulmonary vasculature occurs. The normal pulmonary vasculature is able to accommodate the increased volume of flow by vasodilating and recruiting previously unperfused vessels; thus, pulmonary artery pressures do not rise significantly in most patients with an ASD until adult life [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/5,35\">",
"       5,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to patients with an ASD, clinical sequelae always develop in patients with a large (nonrestrictive) VSD. Severe PAH is present from birth because of the unique hemodynamics. The combined effect of volume overload and shear forces elevates the pulmonary vascular resistance, which becomes fixed during childhood. As a result, shunt reversal (right-to-left flow) is common, with hypoxemia resulting (",
"      <a class=\"graphic graphic_figure graphicRef70502 \" href=\"UTD.htm?33/8/33927\">",
"       figure 4",
"      </a>",
"      ). This is often referred to as the Eisenmenger syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/5,35\">",
"       5,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Injured endothelial cells release factors that are known to contribute to PAH. Inhibition of these factors forms the basis of some of the advanced therapies for PH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Advanced therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma levels of endothelin, a vasoconstrictor and stimulant of vascular smooth muscle cell proliferation, are elevated in patients with PAH due to congenital heart defects (",
"      <a class=\"graphic graphic_figure graphicRef81161 \" href=\"UTD.htm?6/27/6578\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/21\">",
"       21",
"      </a>",
"      ]. Endothelin levels decrease after successful repair of the shunt [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11592?source=see_link\">",
"       \"Role of endothelin in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasma thromboxane B2 levels are also elevated in patients with PAH due to congenital heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/23\">",
"       23",
"      </a>",
"      ]. Thromboxane B2 causes platelet activation and constriction of pulmonary arterioles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Herpesvirus-8",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 (also called Kaposi's sarcoma associated herpesvirus) is a gamma herpesvirus initially identified in Kaposi's sarcoma (KS) lesions from patients infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility that HHV-8 plays a role in the pathogenesis of IPAH was initially suggested by the coexistence of IPAH and multicentric Castleman's disease (another HHV-8-mediated disease) in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/37\">",
"     37",
"    </a>",
"    ]. A subsequent study compared lung biopsies from 16 patients diagnosed with IPAH versus lung biopsies from 12 patients with PH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/38\">",
"     38",
"    </a>",
"    ]. HHV-8 genes and proteins were detected in 10 of 16 patients with IPAH, but none of the patients with PH. However, three subsequent reports failed to confirm an association between IPAH and HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Thus, the role of HHV-8 in the pathogenesis of IPAH remains speculative, and may vary according to environmental factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Human immunodeficiency virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plexogenic arteriopathy can be seen in patients who test positive for antibodies to HIV, even in the absence of acquired immunodeficiency syndrome (AIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The pathogenesis of HIV-associated PAH is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12648?source=see_link&amp;anchor=H4#H4\">",
"     \"Pulmonary hypertension associated with human immunodeficiency virus\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Potassium channel dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that IPAH may result from functional impairment of the voltage-gated potassium channel (Kv) in pulmonary artery smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/45\">",
"     45",
"    </a>",
"    ]. Such impairment could lead sequentially to a change in resting membrane potential, elevation of the intracytoplasmic free calcium concentration, and an increase in pulmonary vascular tone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/46\">",
"     46",
"    </a>",
"    ]. Kv dysfunction may also play an important role in the development of PAH due to anorectic agents (eg, fenfluramine, dexfenfluramine, and aminorex) or PH due to hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     PH second hits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology (including potential second hits) of WHO group 2, 3, 4, or 5 PH is less understood than group 1 PAH. However, it is clear that overlap exists since vascular remodeling and increased pulmonary vascular resistance are present in all groups. This section describes the pathophysiology of two common causes of PH, COPD and heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic obstructive pulmonary disease (COPD) appears to induce PH by increasing pulmonary vascular resistance through two mechanisms: hypoxia-induced vasoconstriction and obliteration of the vascular bed (",
"    <a class=\"graphic graphic_figure graphicRef68045 \" href=\"UTD.htm?43/30/44525\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pulmonary hypoxic vasoconstriction is a normal regulatory mechanism designed to limit blood flow to hypoxic alveoli and preserve ventilation-perfusion matching. Its effect on pulmonary vascular pressure depends on the duration of the hypoxia. Short-term hypoxia causes immediate precapillary arteriole vasoconstriction, which is mediated by mitochondrial signaling in smooth muscle cells and can be fully reversed with oxygen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, chronic hypoxia causes pulmonary vasoconstriction by a variety of mechanisms and is often only partially reversible [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. As an example, correction of hypoxemia with supplemental oxygen in one study decreased the pulmonary vascular resistance and mean pulmonary artery pressure, but only a small amount [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/54\">",
"     54",
"    </a>",
"    ]. Mechanisms by which chronic hypoxia induce vasoconstriction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The endogenous vasodilator, nitric oxide, decreases due to diminished endothelial nitric oxide synthase (eNOS) production and increased hemoglobin mediated inactivation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Production of the voltage-gated potassium channel's alpha subunit or activity of the full transmembrane protein decrease, causing the resting membrane potential to change. As a result, intracellular free calcium increases and pulmonary artery smooth muscles contract (ie, vasoconstriction) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/57-60\">",
"       57-60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cytosolic phospholipase A2 (cPLA2) activity increases, which releases arachidonic acid from phospholipid membranes. Arachidonic acid can then be metabolized by cyclooxygenases and lipoxygenases into a number of different vasoactive eicosanoids, including prostaglandins, thromboxanes, and leukotrienes.",
"     </li>",
"     <li>",
"      Expression of endothelin increases (",
"      <a class=\"graphic graphic_figure graphicRef81161 \" href=\"UTD.htm?6/27/6578\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pathologic changes are consistent with the clinical observation that hypoxic vasoconstriction is initially reversible, but eventually becomes irreversible due to vascular remodeling. Specifically, initial changes include distal neomuscularization of the arterioles, intimal thickening, and medial hypertrophy. Abnormal collagen matrix is deposited within the adventitia later [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The varying degree to which each individual's disease is reversible may explain, in part, why the progression to severe PH and cor pulmonale is unpredictable in patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary venous pressure increases when the left ventricle fails, causing increased pulmonary vascular smooth muscle tone and, to a lesser extent, structural remodeling. The net effect is PH. The same is true with other causes of left atrial hypertension, including mitral and aortic valve disease, left atrial myxoma, pulmonary venous obstruction, restrictive cardiomyopathy, and constrictive pericarditis.",
"   </p>",
"   <p>",
"    With persistent, significant elevation in left atrial and pulmonary venous pressure, pulmonary capillary endothelial cells develop basal laminar thickening. This is followed by interstitial edema and the proliferation of fibrous connective tissue around the alveoli. Later, there is transudation of erythrocytes through ruptured membranes into the alveolar spaces, hemosiderosis, fibrosis, and frank hemorrhage. Two compensatory mechanisms alleviate pulmonary capillary congestion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distension of the pulmonary lymphatics, which clears the increased transudation of fluid induced by the elevated pulmonary venous pressure.",
"     </li>",
"     <li>",
"      Increased pulmonary vascular resistance, which decreases blood flow to the pulmonary capillaries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most patients, increased vascular smooth muscle tone is prominent. It tends to be reversible, to some degree, and is caused by endothelial dysfunction &ndash; diminished synthesis, release, and response to the vasodilator, nitric oxide. This is exacerbated by free radical mediated inactivation of nitric oxide, plus increased production and decreased clearance of the vasoconstrictor, endothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=see_link\">",
"     \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, vascular remodeling occurs and is relatively fixed. It is characterized by medial hypertrophy, intimal hyperplasia, and fibrosis in both the pulmonary arterioles and venules. In one study, medial hypertrophy and neomuscularization of arterioles was shown to occur when pulmonary vascular resistance exceeded 260",
"    <span class=\"nowrap\">",
"     dynes/sec",
"    </span>",
"    per cm5 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/71\">",
"     71",
"    </a>",
"    ]. However, the relationship between the degree of pulmonary vascular resistance and muscular hypertrophy was not linear, suggesting that factors other than medial hypertrophy play a role. Endothelin's major acute effect appears to be increasing the vascular smooth muscle tone; however, it also promotes remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7304/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary hypertension is characterized by elevated pulmonary artery pressure and secondary right ventricular failure. It can be idiopathic or associated with many underlying diseases. There has been significant progress in the understanding of its pathogenesis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The World Health Organization (WHO) classifies patients with pulmonary hypertension into five groups based upon etiology. Patients in the first group are considered to have pulmonary arterial hypertension (PAH), whereas patients in the remaining four groups are considered to have pulmonary hypertension (PH). All five groups are collectively referred to as PH. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PAH is a proliferative disorder that may be secondary to multiple hits, similar to other proliferative disorders such as cancer. There may be similarities in the mechanisms that underlie PAH and other types of PH. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Molecular mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/1\">",
"      Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/2\">",
"      Simonneau G, Gali&egrave; N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/3\">",
"      Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/4\">",
"      Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/5\">",
"      Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/6\">",
"      Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/7\">",
"      Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:13S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/8\">",
"      Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43:25S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/9\">",
"      HEATH D, EDWARDS JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/10\">",
"      Yamaki S, Kumate M, Yonesaka S, et al. Lung biopsy diagnosis of operative indication in secundum atrial septal defect with severe pulmonary vascular disease. Chest 2004; 126:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/11\">",
"      Remetz MS, Cleman MW, Cabin HS. Pulmonary and pleural complications of cardiac disease. Clin Chest Med 1989; 10:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/12\">",
"      Egito ES, Aiello VD, Bosisio IB, et al. Vascular remodeling process in reversibility of pulmonary arterial hypertension secondary to congenital heart disease. Pathol Res Pract 2003; 199:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/13\">",
"      Hoffman JI, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation 1981; 64:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/14\">",
"      Haworth SG, Sauer U, B��hlmeyer K, Reid L. Development of the pulmonary circulation in ventricular septal defect: a quantitative structural study. Am J Cardiol 1977; 40:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/15\">",
"      Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 2005; 111:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/16\">",
"      Machado RD, James V, Southwood M, et al. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005; 111:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/17\">",
"      Austin ED, Loyd JE. Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med 2007; 28:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/18\">",
"      Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/19\">",
"      Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/20\">",
"      Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/21\">",
"      Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 1991; 84:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/22\">",
"      Ishikawa S, Miyauchi T, Sakai S, et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg 1995; 110:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/23\">",
"      Fuse S, Kamiya T. Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation 1994; 90:2952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/24\">",
"      Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/25\">",
"      International PPH Consortium, Lane KB, Machado RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/26\">",
"      Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004; 43:33S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/27\">",
"      Liu D, Wu WH, Mao YM, et al. BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension. Circ Cardiovasc Genet 2012; 5:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/28\">",
"      Kimura N, Matsuo R, Shibuya H, et al. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 2000; 275:17647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/29\">",
"      West J, Fagan K, Steudel W, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004; 94:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/30\">",
"      Lee SD, Shroyer KR, Markham NE, et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/31\">",
"      Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/32\">",
"      Marcos E, Fadel E, Sanchez O, et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004; 94:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/33\">",
"      Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/34\">",
"      Miller VM, Aarhus LL, Vanhoutte PM. Modulation of endothelium-dependent responses by chronic alterations of blood flow. Am J Physiol 1986; 251:H520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/35\">",
"      Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 2002; 89:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/36\">",
"      Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/37\">",
"      Bull TM, Cool CD, Serls AE, et al. Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8. Eur Respir J 2003; 22:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/38\">",
"      Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/39\">",
"      Katano H, Ito K, Shibuya K, et al. Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. J Infect Dis 2005; 191:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/40\">",
"      Laney AS, De Marco T, Peters JS, et al. Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest 2005; 127:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/41\">",
"      Henke-Gendo C, Mengel M, Hoeper MM, et al. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2005; 172:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/42\">",
"      Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/43\">",
"      Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/44\">",
"      Humbert M, Nunes H, Sitbon O, et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/45\">",
"      Yuan XJ, Wang J, Juhaszova M, et al. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998; 351:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/46\">",
"      Yu Y, Fantozzi I, Remillard CV, et al. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A 2004; 101:13861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/47\">",
"      Weir EK, Reeve HL, Huang JM, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/48\">",
"      Weissmann N, Ebert N, Ahrens M, et al. Effects of mitochondrial inhibitors and uncouplers on hypoxic vasoconstriction in rabbit lungs. Am J Respir Cell Mol Biol 2003; 29:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/49\">",
"      Voelkel NF. Mechanisms of hypoxic pulmonary vasoconstriction. Am Rev Respir Dis 1986; 133:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/50\">",
"      Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol 2005; 98:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/51\">",
"      Mauban JR, Remillard CV, Yuan JX. Hypoxic pulmonary vasoconstriction: role of ion channels. J Appl Physiol 2005; 98:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/52\">",
"      Eddahibi S, Hanoun N, Lanfumey L, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000; 105:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/53\">",
"      Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/54\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/55\">",
"      McQuillan LP, Leung GK, Marsden PA, et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994; 267:H1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/56\">",
"      Defouilloy C, Teiger E, Sediame S, et al. Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease. Am J Respir Crit Care Med 1998; 157:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/57\">",
"      Wang J, Juhaszova M, Rubin LJ, Yuan XJ. Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997; 100:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/58\">",
"      Gelband CH, Gelband H. Ca2+ release from intracellular stores is an initial step in hypoxic pulmonary vasoconstriction of rat pulmonary artery resistance vessels. Circulation 1997; 96:3647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/59\">",
"      Post JM, Hume JR, Archer SL, Weir EK. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 1992; 262:C882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/60\">",
"      Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med 1981; 304:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/61\">",
"      Vender RL. Chronic hypoxic pulmonary hypertension. Cell biology to pathophysiology. Chest 1994; 106:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/62\">",
"      Tozzi CA, Poiani GJ, Harangozo AM, et al. Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact endothelium. J Clin Invest 1989; 84:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/63\">",
"      Weir EK, Tucker A, Reeves JT, et al. The genetic factor influencing pulmonary hypertension in cattle at high altitude. Cardiovasc Res 1974; 8:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/64\">",
"      Nattie EE, Doble EA. Threshold of intermittent hypoxia-induced right ventricular hypertrophy in the rat. Respir Physiol 1984; 56:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/65\">",
"      Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. Chest 1991; 99:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/66\">",
"      Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999; 99:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/67\">",
"      Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/68\">",
"      Katz SD, Krum H, Khan T, Knecht M. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996; 28:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/69\">",
"      Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 97:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/70\">",
"      Kay JM, Edwards FR. Ultrastructure of the alveolar-capillary wall in mitral stenosis. J Pathol 1973; 111:239.",
"     </a>",
"    </li>",
"    <li>",
"     Grossman W, Braunwald E. Pulmonary hypertension. In: Heart Disease: A Textbook of Cardiovascular Medicine, 4th ed, Braunwald E (Ed), Saunders, Philadelphia 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7304/abstract/72\">",
"      Komuro I, Kurihara H, Sugiyama T, et al. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238:249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8247 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7304=[""].join("\n");
var outline_f7_8_7304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEMODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MOLECULAR MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PAH second hits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Herpesvirus-8",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Potassium channel dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PH second hits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - COPD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8247|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/47/26352\" title=\"figure 1\">",
"      Simplified current view BMPR-II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/17/23826\" title=\"figure 2\">",
"      Pathophysiology ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/0/12290\" title=\"figure 3\">",
"      Pathophysiology VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/8/33927\" title=\"figure 4\">",
"      Eisenmenger syndrome anatomy and physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/27/6578\" title=\"figure 5\">",
"      Endothelin system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/30/44525\" title=\"figure 6\">",
"      Hypoxic vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8247|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/62/13283\" title=\"picture 1\">",
"      Intimal hyperplasia in PAH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8247|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/38/43628\" title=\"table 1\">",
"      WHO pulmonary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12648?source=related_link\">",
"      Pulmonary hypertension associated with human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11592?source=related_link\">",
"      Role of endothelin in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_8_7305="Pharmacotherapy for panic disorder";
var content_f7_8_7305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for panic disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7305/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7305/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7305/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/8/7305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11968357\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic disorder is a chronic illness characterized by recurrent panic attacks, at least some of which are unexpected, accompanied either by anxiety about having future attacks or about the implications of attacks (eg, undiscovered medical illness, possible sudden death or insanity), or by a change in behavior due to attacks (eg, avoidance of certain situations, recurrent requests for medical tests) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While up to a third of the population will have a panic attack in their lifetime, only about 10 percent of this group (about 3 percent of the population) will go on to develop panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical trials have found that both pharmacologic and psychotherapeutic approaches are efficacious for panic disorder.",
"   </p>",
"   <p>",
"    Pharmacotherapy for panic disorder is discussed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of panic disorder are discussed separately, as is psychotherapy for panic disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link\">",
"     \"Psychotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968364\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classes of medication have shown comparable efficacy for panic disorder, including the selective serotonin reuptake inhibitors (SSRIs), the serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCADs), monoamine oxidase inhibitors (MAOIs), and benzodiazepines. However, these drugs differ in the extent of supporting evidence, side effect profile, and in the case of benzodiazepines, their potential for abuse. These issues are discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, a somewhat poorer response to pharmacologic treatment of panic disorders is seen with more severe illness at baseline, whether severity is characterized by more severe symptoms, longer duration of illness, presence of psychiatric comorbidity (depression, other anxiety disorders, personality disorders), or the presence of social disadvantage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link&amp;anchor=H191515174#H191515174\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Course'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link&amp;anchor=H191515149#H191515149\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968372\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend SSRIs as the first-line medication treatment for panic disorder based on several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The large number of randomized trials demonstrating efficacy for multiple members of this class.",
"     </li>",
"     <li>",
"      Their broad spectrum of action against multiple other comorbidities that commonly occur with panic disorder (eg, major depression, other anxiety disorders). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link&amp;anchor=H191515149#H191515149\">",
"       \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Their relatively benign side effect profile compared to tricyclic antidepressants (TCADs) and monoamine oxidase inhibitors (MAOIs).",
"     </li>",
"     <li>",
"      Their safety in overdose in comparison to TCADs, MAOIs, and possibly serotonin-norepinephrine reuptake inhibitors (SNRIs).",
"     </li>",
"     <li>",
"      The absence of abuse potential and physiological dependence, in contrast to benzodiazepines.",
"     </li>",
"     <li>",
"      The growing availability of less costly generic preparations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968379\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and meta-analysis of 12 trials of acute treatment for panic disorder found the SSRIs to be efficacious compared to placebo, with a medium effect size [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/4\">",
"     4",
"    </a>",
"    ]. Randomized trials have shown",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    to be effective for panic disorder compared to placebo. In general, trials have shown SSRIs to reduce the frequency of panic attacks, severity of anticipatory anxiety, and degree of phobic avoidance &mdash; the core components of panic disorder.",
"   </p>",
"   <p>",
"    As an example, 168 patients with panic disorder with or without agoraphobia were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    or placebo in a 10-week trial. Patients receiving sertraline experienced a greater mean reduction in the number of panic attacks per week compared to patients receiving placebo (88 versus 53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of therapeutic effect of SSRIs is somewhere between 2 and 4 weeks, but clinical response can take up to 8 to 12 weeks for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Trials have shown that therapeutic effects, particularly on anticipatory anxiety and phobic avoidance, can continue to increase over the first 6 to 12 months of treatment in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A number of trials have shown that panic attacks improve before anticipatory anxiety and phobic avoidance; however, other, naturalistic analyses suggest this sequence of response is not always the case [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually every study of SSRIs for panic disorder that has measured phobic avoidance has found comparable reductions on this symptom, suggesting that pharmacotherapy effects for patients with panic disorder with agoraphobia are similar to those for panic disorder patients without agoraphobia.",
"   </p>",
"   <p>",
"    Based on our clinical experience, a second SSRI can be tried if there is no response to an initial agent in this class. There are no data to support this approach in panic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968386\">",
"    <span class=\"h3\">",
"     Within class differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence for superior efficacy in panic disorder among the SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/15\">",
"     15",
"    </a>",
"    ]. Selection of a particular medication should be guided by differences in side effect profile, propensity for medication interactions, half-life, and availability of less expensive, generic preparations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      has a longer half-life (mitigating the effect of missing doses), may be more stimulating for some patients, and can significantly affect blood levels of some medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"      has a short half-life, some anticholinergic effects, and may be more sedating for some patients (which can be useful at bedtime).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       Fluvoxamine",
"      </a>",
"      is uncommonly used to treat panic disorder because its very short half-life requires dosing more than once a day.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"      is more likely to cause diarrhea, has fewer drug interactions than the SSRIs above, and has an intermediate half-life enabling once a day dosing.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       Citalopram",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      are intermediate half-life compounds enabling once a day dosing, and have limited or no propensity to cause drug interactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968393\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because patients with panic disorder are unusually sensitive to overstimulation effects with antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/16\">",
"     16",
"    </a>",
"    ], treatment should be started at low doses (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    5 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    10 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    25 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    10 mg and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    5 mg, all once daily in the morning). If the patient is able to tolerate these doses without anxiety, jitteriness, or insomnia, the doses can be gradually titrated beginning three to seven days after initiation. The SSRI should be titrated to a therapeutic dose over two to six weeks (20 to 40 mg fluoxetine, 20 to 40 mg paroxetine, 100 to 200 mg sertraline, 20 to 40 mg of citalopram and 10 to 20 mg of escitalopram).",
"   </p>",
"   <p>",
"    A trial of an SSRI should be dosed at the lower end of the therapeutic range for two to four weeks; at that point the dose can be increased if clinical improvement is not seen. Increases should occur no faster than at one to two week intervals. Although one small placebo-controlled study did not support",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    dose increases as more effective in non-responsive panic disorder, one should move to the higher end of these dose ranges if there continue to be symptoms at the lower therapeutic doses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the decision is made to discontinue an SSRI for panic disorder, a slow taper over several months is generally recommended. In instances where more rapid taper is desired (eg, patient becomes pregnant and if it is felt that the SSRI should not be continued during pregnancy) then this can be accomplished over several days, if necessary (eg, 150 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    to 50 mg sertraline immediately and then discontinue completely after two to three days), acknowledging that SSRI withdrawal symptoms may ensue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968400\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects are headaches, irritability, gastrointestinal distress (nausea or diarrhea), insomnia and sexual dysfunction. An increased risk of suicidality is seen in patients under age 25. A syndrome of neurologic, gastrointestinal, and psychiatric symptoms can occur if an SSRI is discontinued too quickly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H399779851#H399779851\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968407\">",
"    <span class=\"h2\">",
"     Serotonin-norepinephrine re-uptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the SNRI medications, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    extended release (ER) has been studied in randomized trials of patients with panic disorder, in which it has been shown to be an efficacious treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Venlafaxine reduces all three core components of panic disorder (attack frequency, anticipatory anxiety and phobic avoidance). &nbsp;",
"   </p>",
"   <p>",
"    As an example, 664 nondepressed adults with panic disorder were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ER (75 or 150",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/18\">",
"     18",
"    </a>",
"    ]. After 12 weeks, patients receiving venlafaxine were more likely to be free of full symptom panic attacks compared to patients on placebo (54.4 to 59.7 versus 35.3 percent). Response rates to venlafaxine ER and paroxetine were approximately equal.",
"   </p>",
"   <p>",
"    Because this medication can cause hypertension, particularly at higher doses, and may also be more dangerous in overdose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ER is a second choice for use if SSRIs are ineffective.",
"   </p>",
"   <p>",
"    There is no evidence that the small and subtle advantages of SNRIs over SSRIs observed in depression studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/20\">",
"     20",
"    </a>",
"    ] apply to panic disorder. Some experts believe that the greater noradrenergic effect with higher doses (eg, 225 mg) can be anxiogenic for some panic disorder patients, although there is no systematic study of this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968414\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    ER should be started at no more than 37.5 mg, taken orally in the morning. The immediate release (IR) version of venlafaxine should not be used for panic disorder because of its much greater side effect burden and the difficulty panic disorder patients have tolerating internal bodily sensations and somatic side effects. Dose should be raised to 75 mg at one week, and 150 mg by two to three weeks. This medication has a linear dose response curve in depression studies, and in one of the panic disorder studies the higher dose appeared somewhat more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/18\">",
"     18",
"    </a>",
"    ]. If the clinical response is inadequate after six weeks, the dose should be raised to 225 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968421\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common side effects are nausea, dry mouth, constipation, anorexia, sweating, somnolence and sexual dysfunction. A small number of patients may develop hypertension, particularly at doses of 225 mg or above. Blood pressure should be monitored at regular intervals. Neurologic, gastrointestinal, and psychiatric symptoms can be seen if an SNRI is withdrawn too quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/21\">",
"     21",
"    </a>",
"    ]. SNRIs may have a higher risk of lethal overdose compared with SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968428\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized trials have shown benzodiazepines to effectively reduce each of the three components of panic disorder (attack frequency, anticipatory anxiety and phobic avoidance). In contrast to the weeks needed before the clinical response to SSRIs and SNRIs, benzodiazepines typically take effect within several days and patients will feel an immediate anxiolytic effect within hours. However, this benefit must be balanced against the risks of abuse, the development of physiological dependence, and the existence of a prominent discontinuation syndrome (which is less of a problem with longer acting agents). Patients appear to have more difficulty stopping benzodiazepines and tolerating the effects of discontinuation (which can include hyperarousal, rebound worsening of anxiety, insomnia, tremor and, in its extreme, seizures) compared to SSRIs, which have their own discontinuation syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link&amp;anchor=H16#H16\">",
"     \"Benzodiazepine poisoning and withdrawal\", section on 'Withdrawal'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11968372\">",
"     'Selective serotonin reuptake inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968435\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous randomized trials have found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    (in standard and sustained release formulations),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    to be efficacious for panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/15\">",
"     15",
"    </a>",
"    ]. Meta-analyses have found the effect sizes in these trials to be similar to those seen for SSRIs or tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Onset of the anti-panic effects of benzodiazepines is very rapid, beginning within the first week of treatment. This may be a distinct advantage in severely symptomatic and functionally impaired patients who require rapid relief in order to avoid further clinical deterioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968442\">",
"    <span class=\"h3\">",
"     Within class differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;All agents in this class appear to be equally effective with trials showing comparability among",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/24\">",
"     24",
"    </a>",
"    ]. Only alprazolam and clonazepam are approved by the US FDA for the treatment of panic disorder.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    has several advantages over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    for panic disorder. Clonazepam&rsquo;s longer half-life allows dosing once to twice daily, versus the three to four times daily required for alprazolam. Alprazolam XR, an extended-release formulation of alprazolam, demonstrated to be effective in a controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/25\">",
"     25",
"    </a>",
"    ], requires twice daily dosing according to most clinical experts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/15\">",
"     15",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    Alprazolam is associated with more interdose anxiety, as effects can wear off rapidly in some patients, causing more anxiety before the next dose [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/26\">",
"     26",
"    </a>",
"    ]. When alprazolam&rsquo;s faster onset of action, due to greater lipid solubility and brain penetration, is combined with its short half-life, these effects can strongly reinforce pill-taking to alleviate anxiety, can enhance potential for abuse, and may reduce self-efficacy (ie, patients&rsquo; confidence that they can manage their anxiety on their own). Clonazepam has less intensive symptoms on discontinuation than alprazolam [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968449\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    is typically 0.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    taken orally at bedtime; however, divided doses can be prescribed if there is breakthrough anxiety. The initial dose should be maintained for three to five days to assess for side effects of sedation, psychomotor impairment or concentration difficulties. Increases should be guided by both side effects and therapeutic effects. &nbsp;Most patients will respond to a dose of 1 to 3",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    though some older patients or those with reduced body weight may respond to a lower dose.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     Alprazolam",
"    </a>",
"    can be started at 0.25 mg three to four times daily. After three to five days to assess for side effects, alprazolam can be increased to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses. Despite the labeling, which supports use of alprazolam up to 10 mg, most patients should respond to total doses between 2 and 6",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/28\">",
"     28",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Higher doses should only be considered after a careful search for other factors maintaining panic (eg, medical or psychosocial stress), and after ruling out the possibility of escalating tolerance due to a personal or familial history of substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/29\">",
"     29",
"    </a>",
"    ]. Our clinical experience suggests that the majority of patients with continued anxiety on 3 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    would be unlikely to improve at higher doses.",
"   </p>",
"   <p>",
"    Taper and discontinuation of these medications needs to take place gradually over a course of three to six months, with not more than 10 percent of the dose reduced every two weeks. Physiologic dependence, which occurs with chronic use of benzodiazepines, is described below. (See",
"    <a class=\"local\" href=\"#H11968456\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968456\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are unusually well tolerated compared to other medications for panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/24\">",
"     24",
"    </a>",
"    ]. The side effects consist of sedation, fatigue, psychomotor impairment and reduced memory and concentration. These effects can usually be limited by careful dose adjustment. Patients should be cautioned against operating motor vehicles or heavy machinery during initiation or dose increases. Reported concerns about long-term cognitive impairment with chronic use are not supported by the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of abuse of benzodiazepines is largely confined to individuals with a substance abuse history or problem; though a family history of substance abuse may be a risk factor for some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treating patients who are no longer currently abusing substances with benzodiazepines is not absolutely contraindicated, but would require increased prescription monitoring, increased visit frequency, and the use of more long acting benzodiazepines with slower absorption and onset of action (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment lasting months or more is likely to lead to physiological dependence and consequent withdrawal symptoms if discontinued too quickly. (See",
"    <a class=\"local\" href=\"#H11968449\">",
"     'Dosing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968463\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;This class of antidepressants was the first to be found effective for panic disorder. Because of their greater side effect burden, cardiovascular effects, and morbidity and mortality in overdose, however, they have largely been replaced by the serotonergic antidepressants and benzodiazepines. They are an option for patients who fail to respond to these agents, or are unable to tolerate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968470\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sixteen randomized trials (11 for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    and 5 for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    ) have found tricyclic antidepressants (TCADs) to be superior to placebo in reducing the frequency of panic attacks; their effects on anticipatory anxiety and phobic avoidance has been found to be more variable and, in some cases, less robust [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/3\">",
"     3",
"    </a>",
"    ]. Smaller trials have suggested that other agents in this class are also effective. Most studies of TCADs do not show drug placebo differences until week four with maximal responses by the end of the trial (weeks 8 to 12) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/24\">",
"     24",
"    </a>",
"    ]. Continued improvement has been observed with open label treatment through six months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968484\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     Imipramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    can be started at 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    gradually increased to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    within the first week, and thereafter increased in 25 mg weekly increments to 100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    If there is no response after two to four weeks, the dose can be raised higher in 25 to 50 mg increments up to a total dose of 200",
"    <span class=\"nowrap\">",
"     mg/d.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968491\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;TCADs have a substantial side effect burden and studies have clearly documented poor tolerability compared to SSRIs. The most common side effects are anticholinergic effects, sweating, sleep disturbance, orthostatic hypotension, fatigue and weakness, weight gain, modest blood pressure increases, and sexual dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link&amp;anchor=H19#H19\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968498\">",
"    <span class=\"h2\">",
"     Other antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The irreversible MAO inhibitors (MAOIs) have efficacy against panic disorder, but are infrequently used due to dietary restrictions and side effects.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     Phenelzine",
"    </a>",
"    45",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was found to be effective compared to placebo in a randomized trial of patients with multiple elements of panic disorder (panic attacks, anxiety, and phobias) before the DSM diagnosis was established [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/32\">",
"     32",
"    </a>",
"    ]. Based on clinical experience, we consider a dose of 60 mg to be more effective.",
"   </p>",
"   <p>",
"    There are no empirical data to support the perception among some clinicians that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    may be especially useful in treatment resistant cases. The irreversible MAOIs require a restricted diet and avoidance of certain medications. MAOIs should not be taken concurrently with serotonergic antidepressants. The use and adverse effects of these agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The newer, reversible MAOI agents, brofaromine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/5/18518?source=see_link\">",
"     moclobemide",
"    </a>",
"    , have been shown to be superior to placebo in some, but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/15\">",
"     15",
"    </a>",
"    ]. Neither of these drugs is available in the US.",
"   </p>",
"   <p>",
"    Randomized trials have not generally supported the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/15,24\">",
"     15,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968505\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials support the use of anticonvulsants for panic disorder, with negative trials for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/33\">",
"     33",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/34\">",
"     34",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/35\">",
"     35",
"    </a>",
"    ]. A post-hoc analysis suggested that gabapentin may have efficacy in more severe forms of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/35\">",
"     35",
"    </a>",
"    ], but this remains to be determined.",
"   </p>",
"   <p>",
"    Trials have found monotherapy with beta-blockers or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , an alpha-2 noradrenergic agonist, to be no more effective for panic disorder than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11968519\">",
"     'Medication combinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The absence of randomized trials of second-generation antipsychotics for panic disorder, combined with growing concern about the side effects of these agents, suggests that they should not be used as monotherapy for the disorder. The role of these drugs in combination with other antipanic drugs for treatment refractory cases remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968512\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies that systematically address the optimal duration of treatment, but available evidence suggests that effective pharmacotherapy for panic disorder should be continued for at least one year after symptom control has been attained.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies have found that symptoms continue to improve over the first 6 months of treatment with an SSRI, SNRI, or TCAD; many studies suggest that improvement continues between months 6 and 12 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/12,31,38\">",
"       12,31,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of 6 randomized discontinuation trials with 796 patients treated for panic disorder with an SSRI, SNRI, or TCAD strongly favored antidepressant continuation over replacement with a placebo during the first year of treatment (odds ratio=0.35, 95% CI 0.23-0.51) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/39\">",
"       39",
"      </a>",
"      ]. Relapse rates following antidepressant discontinuation were approximately 25 to 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/12,40,41\">",
"       12,40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relapse rates following discontinuation of benzodiazepine treatment for panic disorder have been much higher (70 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/42\">",
"       42",
"      </a>",
"      ]. These results are more difficult to validate because symptoms that follow discontinuation can reflect either transient withdrawal symptoms or re-emergence of panic anxiety.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with more severe panic disorder should receive treatment at the longer end of the one to two year range, whether severity is characterized by duration of illness, intensity of symptoms, or the presence of Axis I or II comorbidities, residual symptoms, or medical or psychosocial stressors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968519\">",
"    <span class=\"h1\">",
"     MEDICATION COMBINATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are little data on combining medications to treat panic disorder. Two placebo controlled trials have demonstrated that augmenting acute-phase antidepressant treatment with four to six weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    results in more rapid symptom resolution compared to placebo augmentation, but no difference in outcome by 8 to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Use of the short half-life alprazolam produced expected worsening of anxiety symptoms during fairly rapid, two week discontinuation. Discontinuation and taper with clonazepam was more easily tolerated.",
"   </p>",
"   <p>",
"    A small randomized trial found that adding the beta-blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    to the treatment of patients with panic disorder who had not responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    resulted in symptom reduction compared to placebo augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/36\">",
"     36",
"    </a>",
"    ]. Because pindolol also is a serotonin 1A receptor agonist, it is possible that beta-blockade is unrelated to anti-panic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166005797\">",
"    <span class=\"h1\">",
"     COMPARING MEDICATION TO CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT and antidepressant medication have been shown in controlled trials to be equally effective in the treatment of panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7305/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link&amp;anchor=H898870663#H898870663\">",
"     \"Psychotherapy for panic disorder\", section on 'Comparing CBT to medication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968526\">",
"    <span class=\"h1\">",
"     COMBINED MEDICATION AND CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of CBT (or in some cases, behavioral therapy) and antidepressant treatment has shown a small advantage in the short term over either CBT alone or antidepressants alone for panic disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link&amp;anchor=H69301556#H69301556\">",
"     \"Psychotherapy for panic disorder\", section on 'Combined CBT and medication'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the use of combined medication and CBT for patients with panic disorder with comorbid posttraumatic stress disorder, depression, or suicidality as well as for patients with panic disorder who have persistent symptoms after adequate trials of pharmacotherapy. This suggestion is based upon our clinical experience; there are no trials on response to combined versus individual treatments specific to these subgroups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link&amp;anchor=H191515149#H191515149\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/10/13473?source=see_link\">",
"       \"Patient information: Panic disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11968638\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend initial treatment of panic disorder with an antidepressant, cognitive behavioral therapy (CBT), or a combination of the two (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Selection among these options can be made on the basis of patient preference and treatment availability. (See",
"      <a class=\"local\" href=\"#H166005797\">",
"       'Comparing medication to CBT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11968526\">",
"       'Combined medication and CBT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link\">",
"       \"Psychotherapy for panic disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest the use of combined antidepressant medication and CBT for patients with panic disorder with comorbid posttraumatic stress disorder, depression, or suicidality as well as for patients with panic disorder who have persistent symptoms after adequate trials of pharmacotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11968526\">",
"       'Combined medication and CBT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link&amp;anchor=H191515149#H191515149\">",
"       \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      We suggest use of a selective serotonin reuptake inhibitor (SSRI) as first-line medication treatment of panic disorder (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The SSRIs",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      have shown comparable effectiveness compared to placebo. Selection among them should be guided by differences in side-effect profile, metabolic interactions, half-life, or cost. (See",
"      <a class=\"local\" href=\"#H11968386\">",
"       'Within class differences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Starting doses should be low and titration gradual in order to avoid symptom exacerbation. As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      can be started at 10",
"      <span class=\"nowrap\">",
"       m/day",
"      </span>",
"      and should be advanced to the therapeutic range (20 to 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      over two to six weeks. (See",
"      <a class=\"local\" href=\"#H11968393\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A second SSRI can be tried if there is no response to an initial agent in this class. (See",
"      <a class=\"local\" href=\"#H11968379\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest use of the serotonin-norepinephrine reuptake inhibitor (SNRI)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      extended release for panic disorder that has not responded to trials of an SSRI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       Venlafaxine",
"      </a>",
"      ER can be started at 37.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and increased to 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      after a week and to 150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      over two to three weeks. If the clinical response is inadequate after six weeks, the dose can be raised to 225",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H11968407\">",
"       'Serotonin-norepinephrine re-uptake inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with severe panic disorder and associated disability that has either not responded to an SSRI or SNRI, or cannot wait for the time required for them to work, we suggest treatment with a benzodiazepine (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      1 to 3",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      0.5 to 2.0 mg tid). Active substance abuse is a contraindication for benzodiazepines; these medications should be prescribed carefully in patients with a history of substance abuse. (See",
"      <a class=\"local\" href=\"#H11968428\">",
"       'Benzodiazepines'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29993?source=see_link\">",
"       \"Treatment of co-occurring anxiety disorders and substance use disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The benefits of benzodiazepines (efficacy comparable to the serotonergic agents without their two to four week delay prior to clinical response) must be weighed against the risks of abuse, the development of physiological dependence, and the existence of a prominent discontinuation syndrome.",
"     </li>",
"     <li>",
"      A long acting benzodiazepine can also be used in conjunction with a serotonergic antidepressant in the first weeks of treatment, before the antidepressant takes effect, in patients with marked distress or impairment, and no history of benzodiazepine or prescription drug abuse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tricyclic antidepressants are effective for panic disorder but are more poorly tolerated than SSRIs, with adverse somatic effects that may trigger these patients&rsquo; intolerance of internal bodily sensations, possibly exacerbating their panic. (See",
"      <a class=\"local\" href=\"#H11968463\">",
"       'Tricyclic antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Duration of pharmacotherapy should be at least one year after symptom control has been attained. Decisions about discontinuation should be based a prior history of relapse and the presence of risk factors for relapse, including the severity of the initial syndrome or the presence of psychiatric comorbidity (depression, agoraphobia, or personality disorder), ongoing psychosocial or medical stress, and any residual symptoms of phobia, anticipatory anxiety or subclinical panic. (See",
"      <a class=\"local\" href=\"#H11968512\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/2\">",
"      Norton CR, Cox BJ, Malan J. Nonclinical panickers: A critical review. Clin Psychol Rev 1992; 12:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/3\">",
"      Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002; 106:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/4\">",
"      Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001; 158:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/5\">",
"      Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005; 88:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/6\">",
"      Wilkinson G, Balestrieri M, Ruggeri M, Bellantuono C. Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychol Med 1991; 21:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/7\">",
"      Slaap BR, den Boer JA. The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress Anxiety 2001; 14:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/8\">",
"      Roy-Byrne PP, Russo J, Cowley DS, Katon WJ. Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. J Clin Psychiatry 2003; 64:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/9\">",
"      Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998; 155:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/10\">",
"      Michelson D, Allgulander C, Dantendorfer K, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 2001; 179:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/11\">",
"      Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/12\">",
"      Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001; 104:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/13\">",
"      Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/14\">",
"      Deltito JA, Argyle N, Buller R, et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Compr Psychiatry 1991; 32:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/15\">",
"      Stein M, Goin M, Pollack M, et al. Practice Guideline for the treatment of patients with panic disorder: Second edition. Am J Psychiatry 2009; 166 (2):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/16\">",
"      Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry 1997; 58:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/17\">",
"      Simon NM, Otto MW, Worthington JJ, et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry 2009; 70:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/18\">",
"      Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/19\">",
"      Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005; 187:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/20\">",
"      Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007; 22:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/21\">",
"      Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 2006; 67 Suppl 4:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/22\">",
"      Cheeta S, Schifano F, Oyefeso A, et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004; 184:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/23\">",
"      Rubino A, Roskell N, Tennis P, et al. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007; 334:242.",
"     </a>",
"    </li>",
"    <li>",
"     Roy-Byrne PP, Cowley D. Pharmcologic treatments for panic disorder, generalized anxiety disorders, specific phobia and social anxiety disorders. In: A guide to treatments that work, 3rd ed, Nathan P, Gorman J.  (Eds), Oxford University Press, New York 2007. p.337.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/25\">",
"      Schweizer E, Patterson W, Rickels K, Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993; 150:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/26\">",
"      Herman JB, Brotman AW, Rosenbaum JF. Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. J Clin Psychiatry 1987; 48 Suppl:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/27\">",
"      Herman JB, Rosenbaum JF, Brotman AW. The alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol 1987; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/28\">",
"      Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992; 12:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/29\">",
"      Ciraulo DA, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry 1988; 145:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/30\">",
"      Verdoux H, Lagnaoui R, Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 2005; 35:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/31\">",
"      Zitrin CM, Klein DF, Woerner MG, Ross DC. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983; 40:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/32\">",
"      Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/33\">",
"      Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/34\">",
"      Zwanzger P, Eser D, Nothdurfter C, et al. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry 2009; 42:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/35\">",
"      Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/36\">",
"      Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000; 20:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/37\">",
"      Uhde TW, Stein MB, Vittone BJ, et al. Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 1989; 46:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/38\">",
"      Lepola U, Bergtholdt B, St Lambert J, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004; 65:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/39\">",
"      Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord 2010; 123:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/40\">",
"      Ferguson JM, Khan A, Mangano R, et al. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 2007; 68:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/41\">",
"      Mavissakalian MR, Perel JM. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1999; 56:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/42\">",
"      Noyes R Jr, Garvey MJ, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991; 148:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/43\">",
"      Woods SW, Nagy LM, Koleszar AS, et al. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol 1992; 12:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7305/abstract/44\">",
"      Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58:681.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14630 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7305=[""].join("\n");
var outline_f7_8_7305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11968638\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11968357\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11968364\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11968372\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968379\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968386\">",
"      - Within class differences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968393\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968400\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11968407\">",
"      Serotonin-norepinephrine re-uptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968414\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968421\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11968428\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968435\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968442\">",
"      - Within class differences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968449\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968456\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11968463\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968470\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968484\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11968491\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11968498\">",
"      Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11968505\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11968512\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11968519\">",
"      MEDICATION COMBINATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H166005797\">",
"      COMPARING MEDICATION TO CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11968526\">",
"      COMBINED MEDICATION AND CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11968638\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/10/13473?source=related_link\">",
"      Patient information: Panic disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=related_link\">",
"      Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=related_link\">",
"      Psychotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29993?source=related_link\">",
"      Treatment of co-occurring anxiety disorders and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_8_7306="Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse";
var content_f7_8_7306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7306/contributors\">",
"     Sangeeta T Mahajan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7306/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/8/7306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/8/7306/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/8/7306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior vaginal wall prolapse describes support abnormalities of the anterior wall of the vagina. Prolapse of the anterior wall typically coexists with prolapse at other anatomic sites (vaginal apex, posterior vaginal wall) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevailing view is that a common pathogenesis underlies support defects at different sites of the vaginal wall, replacing a previous focus on isolated anatomic compartments. Procedures for surgical repair of anterior vaginal wall defects should include repair of apical prolapse, if present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pelvic organ prolapse (POP) affects millions of women; approximately 200,000 inpatient surgical procedures for prolapse are performed annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Eleven to 19 percent of women will undergo surgery for prolapse or urinary incontinence by age 80 to 85 years, and 30 percent of these women will require an additional prolapse or incontinence surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reconstructive procedures for prolapse of the anterior vaginal wall are reviewed here. Related topics regarding POP in women are discussed separately, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis and evaluation and conservative management (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link\">",
"       \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=see_link\">",
"       \"Vaginal pessary treatment of prolapse and incontinence\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Choosing a primary surgical procedure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=see_link\">",
"       \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Obliterative procedures (colpocleisis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43607?source=see_link\">",
"       \"Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1630899\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Continence Society defines",
"    <strong>",
"     anterior vaginal wall defects",
"    </strong>",
"    as descent of the anterior vagina so that the urethrovesical junction or any other point on the anterior vaginal wall is less than 3 cm from the hymenal ring [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/6\">",
"     6",
"    </a>",
"    ]. Clinically, any abnormal descent of the anterior vaginal wall or bladder base with or without straining may be considered an anterior vaginal wall defect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current designation reflects the actual site of vaginal wall prolapse (anterior vaginal wall), rather than the structures underlying it (bladder or urethra), and has replaced previously used terms, such as",
"    <strong>",
"     cystocele",
"    </strong>",
"    or",
"    <strong>",
"     urethrocele",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1631916\">",
"    <span class=\"h1\">",
"     ANATOMY AND MECHANISMS OF INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Normal anterior wall support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper two-thirds of the vagina is supported by the underlying levator ani muscles (pubococcygeus, puborectalis, and iliococcygeus) and a layer of dense fibrous musculoconnective tissue (the endopelvic fascia), which surrounds the cervix and vagina and extends laterally to the arcus tendineus fasciae pelvis (also called the \"white line\") on each side (",
"    <a class=\"graphic graphic_figure graphicRef62230 \" href=\"UTD.htm?31/63/32756\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The arcus tendineus fasciae pelvis runs from the ischial spine to the inferior margin of the pubic symphysis. Despite common misconceptions, there is no vaginal fascia, only three distinct vaginal layers consisting of mucosa, muscularis, and adventitia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The bladder has no true support structures of its own and simply overlies the upper one-third of the vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/9\">",
"     9",
"    </a>",
"    ]. The urethra is supported by the anterior vaginal wall and the surrounding urethrovaginal sphincter and compressor urethrae [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomy of the female pelvic floor is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H690213#H690213\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Anatomy of pelvic support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis of anterior wall defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, anterior vaginal wall defects were believed to be due to stretching or thinning of the anterior vaginal wall and its supports, thereby allowing herniation of the bladder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urethra into the vagina (",
"    <a class=\"graphic graphic_figure graphicRef62745 \" href=\"UTD.htm?14/63/15349\">",
"     figure 2",
"    </a>",
"    ). The approach to treatment based upon this assumption was surgical plication or tightening of the weak and redundant anterior vaginal wall (ie, anterior colporrhaphy) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current understanding of anterior vaginal wall prolapse is that the etiology is not an overall stretch defect, but is the result of a specific defect in the support structures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Lack of attention to the specific defect in these support structures has been proposed as a major reason that anterior vaginal wall prolapse recurs in as many as 40 percent of patients after anterior colporrhaphy alone or because the apex has also not been addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. The concept of a site-specific defect has replaced prior theories on the pathogenesis of anterior vaginal wall defects and altered evaluation and management of anterior vaginal prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Site-specific defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four anatomic sites of anterior vaginal support abnormalities were originally described by Richardson in 1976. Clinical practice and research have focused on midline and paravaginal sites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], although these &ldquo;sites&rdquo; are difficult to study in isolation. The ability to diagnose these defects has not been well studied or validated. Midline and paravaginal defects are defined as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Midline",
"      </strong>",
"      &ndash; Midline defects (also referred to as central) arise from vertical defects in the endopelvic fascia (musculoconnective tissue) extending anteriorly to posteriorly (",
"      <a class=\"graphic graphic_figure graphicRef68850 \" href=\"UTD.htm?16/29/16852\">",
"       figure 3",
"      </a>",
"      ). They often interrupt support of the urethrovesical junction, contributing to urethral hypermobility and stress urinary incontinence (SUI) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      On examination, a central defect is visualized as an anterior vaginal wall defect, but the lateral vaginal fornices are intact bilaterally (ie, a large anterior wall bulge still firmly connected to the lateral pelvic sidewalls).",
"     </li>",
"     <li>",
"      <strong>",
"       Paravaginal",
"      </strong>",
"      &ndash; Paravaginal defects (also referred to as lateral) result from detachment of the lateral vaginal wall from the arcus tendineus fascia pelvis (",
"      <a class=\"graphic graphic_figure graphicRef68850 \" href=\"UTD.htm?16/29/16852\">",
"       figure 3",
"      </a>",
"      ). As a result, the lateral vaginal sulcus descends, often accompanied by a moderate anterior wall prolapse, loss of the urethrovesical angle, and significant SUI. This type of defect can occur unilaterally or bilaterally [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/17,19\">",
"       17,19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The presence of a paravaginal defect is assessed using a tongue depressor (or ring forceps). The tongue depressor (or ring forceps) is placed in the lateral anterior vaginal sulcus and then elevated. If the anterior wall defect resolves, then this suggests lateral separation of the vagina from the arcus tendineus fascia pelvis. Both vaginal sulci should be checked, as vaginal defects may occur unilaterally or bilaterally. In contrast, a persistent anterior wall defect despite supporting the lateral vaginal sulcus suggests a central or transverse defect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other site-specific defects that have been described include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transverse &ndash; Transverse defects occur when the pubocervical fascia separates from its insertion into the ring of connective tissue around the cervix and uterosacral ligaments, creating a transverse support defect and loss of the anterior fornix of the cervix (",
"      <a class=\"graphic graphic_figure graphicRef68850 \" href=\"UTD.htm?16/29/16852\">",
"       figure 3",
"      </a>",
"      ). On examination, these defects often result in a large anterior vaginal wall defect, which appears to originate high on the anterior vaginal wall or near the cervix (also referred to as a high cystocele), although the urethra may remain well supported [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Distal &ndash; Distal defects are the least common forms of anterior vaginal wall defects. They are due to a break in the fibromuscular support of the anterior vaginal wall, just before the insertion into the pubic symphysis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/7\">",
"       7",
"      </a>",
"      ]. These defects tend to be smaller and include the distal anterior vaginal wall (ie, near the introitus) and usually are associated with urethral hypermobility [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaginal wall abnormalities may be further divided into anterior or posterior. An anterior defect represents descent of the urethra and bladder neck with straining while a posterior defect represents descent of the bladder base [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4650631\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR ANTERIOR PROLAPSE REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with bothersome symptoms attributable to anterior vaginal wall prolapse that decline or fail conservative therapy are candidates for surgical repair. Surgical correction of asymptomatic pelvic organ prolapse (POP) or non-bothersome POP is of uncertain benefit and exposes patients to operative risk. Prolapse repair is typically deferred until after a woman completes childbearing.",
"   </p>",
"   <p>",
"    Indications and contraindications for POP repair are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=see_link&amp;anchor=H2327205#H2327205\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Candidates for surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2157028\">",
"    <span class=\"h1\">",
"     SURGICAL PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues specific to planning repair of apical prolapse are discussed in this section. General principles of surgical decision-making regarding pelvic organ prolapse (POP) (eg, obliterative versus reconstructive surgery, concomitant hysterectomy, concomitant anti-incontinence surgery) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=see_link\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2157038\">",
"    <span class=\"h2\">",
"     Site-specific repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior vaginal wall POP may be due to defects that are central, lateral, transverse, or distal, as described above. The procedure or combination of procedures used depends upon the specific site of the defect. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Site-specific defects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2157046\">",
"    <span class=\"h2\">",
"     Concomitant repair of other sites of prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior vaginal wall defects rarely occur in isolation and are often accompanied by descent of the vaginal apex or posterior vaginal wall. The need for repair of other anatomic sites of prolapse is guided by the preoperative evaluation. Currently, most pelvic surgeons agree that apical support must be carefully evaluated preoperatively in all patients to determine whether an apical suspension is indicated. Studies have demonstrated significantly improved anterior and posterior prolapse repair outcomes when performed concurrently with an apical support repair, transvaginal or transabdominal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/21\">",
"     21",
"    </a>",
"    ]. This is discussed in detail separately.",
"   </p>",
"   <p>",
"    Patients should be carefully examined in the office prior to surgery in order to assess whether there are support defects of the vaginal apex (cervix or vaginal vault) or posterior vaginal wall, in addition to an anterior vaginal wall support defect. If significant apical prolapse is noted, an apical repair procedure should be performed at the time of surgery. When apical repair is performed via an abdominal route (sacrocolpopexy), most surgeons will perform this portion of the procedure first and then proceed with an anterior colporrhaphy. This follows the principle of moving from a clean field (abdominal) to a clean contaminated field (vaginal) to decrease the risk of surgical site infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=see_link&amp;anchor=H2327483#H2327483\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Concomitant repair of apical and anterior or posterior prolapse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H21188619#H21188619\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Concomitant repair of other sites of prolapse'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4650894\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation for women planning surgical repair of anterior vaginal wall pelvic organ prolapse (POP) should address the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence and severity of symptoms &ndash; The goal of POP repair is to correct anatomic defects that result in bothersome symptoms. A detailed discussion with the patient allows the surgeon to differentiate symptoms that affect the patient&rsquo;s quality of life from those that are mild and not bothersome. Whenever possible, it is important to identify symptoms that are attributable to a specific anatomic compartment, since this aids surgical decision-making. As an example, women with advanced anterior and apical prolapse may experience urinary retention, but this is not associated with posterior vaginal wall prolapse. Prolapse is often present in more than one anatomic compartment (anterior, posterior, vaginal apex), however, and many symptoms are not specific to a single site [",
"      <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anatomic site and degree of prolapse &ndash; POP is often present at more than one anatomic compartment and a coordinated approach to repair may be required. All potential defect areas must be assessed prior to surgery, especially the vaginal apex. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=see_link&amp;anchor=H2327483#H2327483\">",
"       \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Concomitant repair of apical and anterior or posterior prolapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Presence of associated conditions &ndash; POP often coexists with urinary tract or bowel dysfunction (eg, incontinence, urinary retention, constipation). Relevant symptoms should be elicited and further evaluation performed as appropriate. In addition, preoperative sexual function concerns should be discussed with the patient. Sexual dysfunction may be associated with POP. In addition, some women may experience dyspareunia or other alterations in sexual function following POP repair. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link&amp;anchor=H7155701#H7155701\">",
"       \"Pelvic organ prolapse in women: Diagnostic evaluation\", section on 'Urinary tract evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link&amp;anchor=H7155823#H7155823\">",
"       \"Pelvic organ prolapse in women: Diagnostic evaluation\", section on 'Bowel function evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aspects of preoperative evaluation and preparation that are specific to anterior prolapse repair are discussed in this section. General principles of evaluation of women with POP are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4650902\">",
"    <span class=\"h2\">",
"     Informed consent and patient goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgeons should discuss the goals and expected outcomes of treatment with the patient. This helps to set realistic expectations and assess postoperative improvement. Patient satisfaction after surgery for POP and urinary incontinence correlates highly with achievement of self-described preoperative surgical goals, but poorly with objective outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Informed consent should include a discussion of alternative treatments, the expected efficacy of the procedure, and the risk of surgical complications. If use of surgical mesh or a biograft is planned, the relative efficacy of this to native tissue repair and the risk of mesh-related complications should be reviewed. (See",
"    <a class=\"local\" href=\"#H1936017\">",
"     'Use of reconstructive materials'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4650910\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms associated with prolapse and associated conditions (urinary, bowel, sexual function) should be elicited. The most common clinical manifestation of prolapse of the anterior vaginal wall is a bulge or protrusion from the vagina (",
"    <a class=\"graphic graphic_picture graphicRef77424 \" href=\"UTD.htm?19/62/20449\">",
"     picture 1",
"    </a>",
"    ). Protrusion of the vagina may result in vaginal discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding from ulceration. Other symptoms frequently reported by women with anterior prolapse are urinary incontinence or voiding difficulty; some women need to reduce the prolapse using a finger in the vagina (ie, &ldquo;splint&rdquo;) to urinate or defecate.",
"   </p>",
"   <p>",
"    Women with urinary tract symptoms should undergo appropriate evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link&amp;anchor=H7155701#H7155701\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\", section on 'Urinary tract evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General symptoms of POP are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H21524755#H21524755\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4650918\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolapse commonly involves two or more anatomic sites. A thorough speculum and bimanual pelvic examination should be performed. The findings of the examination should be recorded using a quantitative and reproducible method for recording POP. The system currently recommended by the International Continence Society and the American Urogynecologic Society (AUGS) is the POP quantitation (POP-Q) system (",
"    <a class=\"graphic graphic_figure graphicRef74368 \" href=\"UTD.htm?14/54/15202\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57450 \" href=\"UTD.htm?3/1/3100\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination for site-specific defects is discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Site-specific defects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The physical examination for assessment of POP is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link&amp;anchor=H2#H2\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\", section on 'Speculum and bimanual examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1934772\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation and imaging are not typically necessary for evaluation of anterior vaginal wall prolapse. Preoperative testing should be performed as needed based upon patient age and medical comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25711790\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25711799\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend antibiotic prophylaxis for surgical site infection for procedures for the treatment of pelvic organ prolapse (POP) or stress urinary incontinence (SUI). Infectious complications of such procedures include urinary tract infection, wound infection, or infections associated with reconstructive materials (eg, abscess, cellulitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/27-32\">",
"     27-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale of antibiotic prophylaxis in pelvic reconstructive procedures varies somewhat with the surgical route. The vaginal field is classified as clean-contaminated. There are few direct data that address transvaginal pelvic floor surgery. The only randomized trial evaluated use of prophylactic antibiotics for midurethral sling placement and found no significant differences in rates of bacteriuria or wound infection in women treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    compared with placebo, but the study was underpowered to detect these differences [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/33\">",
"     33",
"    </a>",
"    ]. Indirect evidence derives from studies of vaginal hysterectomy, which involves the same surgical field. A meta-analysis of studies of vaginal hysterectomy found a decrease in pelvic infections with use of prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of surgical site infection for procedures involving reconstructive materials (mesh, biografts) is discussed in detail separately.",
"   </p>",
"   <p>",
"    Transabdominal pelvic reconstructive surgeries that do not involve a vaginal incision (eg, sacral colpopexy) are classified as clean procedures. There is no direct evidence about the use of prophylactic antibiotics for these procedures, but the risk of infection is likely similar to other transabdominal pelvic surgery. A meta-analysis of 25 randomized trials of abdominal hysterectomy found a significant decrease in serious postoperative infections with use of antibiotics (9 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our recommendation is consistent with professional society guidelines. American College of Obstetricians and Gynecologists (ACOG) guidelines advise antibiotic prophylaxis for surgical site infection for urogynecologic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/36\">",
"     36",
"    </a>",
"    ]. American Urological Association (AUA) guidelines also advise use of antibiotic prophylaxis for all patients undergoing vaginal urologic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Procedures for the treatment of POP or SUI do not require antibiotic prophylaxis of bacterial endocarditis, in the absence of other indications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H22969468#H22969468\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25712025\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedures for repair of anterior vaginal prolapse that are classified as minor surgery (defined as &lt;30 minutes) and are performed in mobile patients with no additional thrombotic risk factors are classified as low risk for venous thromboembolism and do not require specific thromboprophylaxis. For procedures with a duration of 30 or more minutes, intermittent pneumatic compression or pharmacologic thromboprophylaxis is recommended by the American College of Chest Physicians (ACCP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H17332175#H17332175\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25712074\">",
"    <span class=\"h2\">",
"     Other measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many surgeons treat postmenopausal women with transvaginal estrogen preoperatively to maximize vaginal mucosal thickness at the time of surgery and postoperatively to facilitate tissue healing. There are not data regarding the safety or efficacy of this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vaginal atrophy\", section on 'Vaginal estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1936642\">",
"    <span class=\"h1\">",
"     MIDLINE DEFECT REPAIR (ANTERIOR COLPORRHAPHY)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior colporrhaphy (also referred to as anterior repair) is the procedure of choice for repair of midline, or central, anterior vaginal wall defects",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to reduce the volume of the anterior wall. This procedure may be combined with paravaginal or transverse defect repair, depending upon the sites of vaginal support defects in the individual patient. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Site-specific defects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19854837\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior colporrhaphy involves some degree of excision",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plication of redundant anterior vaginal wall mucosa (epithelium).",
"   </p>",
"   <p>",
"    There are many variations in technique; the following is the approach we use in our practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is placed in the dorsal lithotomy position. A bladder catheter is placed. A weighted speculum or self-retaining retractor is placed within the vagina, allowing adequate visualization of the anterior vaginal wall.",
"     </li>",
"     <li>",
"      An Allis clamp is placed 1 cm proximal to the urethra along the midline of the anterior vagina and two more Allis clamps on either side of the vaginal cuff or just distal to the cervix. The anterior vaginal wall may be injected with saline or a solution of diluted vasopressin (eg, 20 units of vasopressin in 100 ml of saline), if desired to assist in identifying planes of dissection. Safe practices for use of vasopressin are described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H4413358#H4413358\">",
"       \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'Vasopressin and other vasoconstrictors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A transverse incision is made between the two Allis clamps on the vaginal",
"      <span class=\"nowrap\">",
"       cuff/cervix.",
"      </span>",
"      Metzenbaum scissors are then used to dissect the vaginal mucosa off the underlying tissues anteriorly (",
"      <a class=\"graphic graphic_figure graphicRef69730 \" href=\"UTD.htm?13/23/13684\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Once adequate mobility of the vaginal mucosa is achieved, a small vertical incision is made with Metzenbaum scissors in the midline, perpendicular to the initial incision. The scissors are then carefully placed beneath the most superficial layer possible in the anterior vaginal wall mucosa and advanced with gentle pressure for 2 to 3 centimeters. The scissors are spread slightly as they are withdrawn, thereby assisting in dissection of the vaginal mucosa from the underlying tissue. The path of the scissors is incised, extending the vertical incision.",
"     </li>",
"     <li>",
"      This process is repeated until the level of the Allis clamp proximal to the urethra is reached. Additional Allis clamps are placed on the mucosal edges to assist in retraction. Once completed, further dissection of the mucosa from the underlying tissues is performed bilaterally until the mucosa has been dissected off the entirety of the bladder. Care should be taken to limit the dissection to the extent needed to correct the defect. Excessive dissection may increase the risk of denervation injury to the bladder.",
"     </li>",
"     <li>",
"      Plication of the vaginal muscularis and adventitia is then performed using figure-of-eight sutures; some people run the suture placed as laterally as possible in the field of dissection, but deep enough to include only vaginal adventitia and muscularis and not bladder mucosa. Delayed absorbable sutures (eg, 0-0 Vicryl&reg;, PDS) are most often used and are tied in the midline. Multiple layers of closure may be used for larger defects. Care should be taken to avoid excessive tissue plication around the urethra, to avoid obstruction.",
"     </li>",
"     <li>",
"      Once plication of the defect has been performed, redundant vaginal mucosa may be trimmed. Excessive reduction in vaginal diameter should be avoided, as it may result in significant dyspareunia. At procedure completion, the surgeon should be able to easily insert two fingers in the vagina. The vaginal incision is closed with a fine delayed absorbable suture (eg, 3-0 Monocryl&trade;).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women with stress urinary incontinence (SUI), it had been a common practice to perform a Kelly bladder neck plication at the time of anterior colporrhaphy. However, randomize trial data show that anterior colporrhaphy alone or with a Kelly (or Kelly-Kennedy) plication is not an effective anti-incontinence procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H9#H9\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Procedures no longer recommended'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anterior colporrhaphy is typically performed transvaginally, with few exceptions. Use of a transabdominal approach at the time of concurrent abdominal surgery (hysterectomy, Burch urethropexy) has been reported. In this approach, the surgeon excises a triangle-shaped wedge of the anterior vaginal cuff (wide base at the level of the cuff and narrowing distally). The transabdominal approach has been evaluated in few studies, which found high recurrence rates at five years after surgery (61 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1636600\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are lacking regarding the incidence of perioperative complications of anterior colporrhaphy. Potential complications include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhage",
"     </li>",
"     <li>",
"      Bladder, urethral, or ureteral injury",
"     </li>",
"     <li>",
"      Hematoma",
"     </li>",
"     <li>",
"      Wound infection or dehiscence",
"     </li>",
"     <li>",
"      Vaginal pain or dyspareunia",
"     </li>",
"     <li>",
"      Urinary tract infection",
"     </li>",
"     <li>",
"      De novo or worsening detrusor overactivity",
"     </li>",
"     <li>",
"      Urinary retention",
"     </li>",
"     <li>",
"      Urogenital fistula",
"     </li>",
"     <li>",
"      Urethral diverticulum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If reconstructive materials are used, the risk of complications increases and may include mesh erosion, mesh contracture, and mesh-related infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1243210\">",
"    <span class=\"h3\">",
"     Hemorrhage or hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative complications are rare for anterior colporrhaphy, but hemorrhage requiring transfusion may occur. The vaginal plexus and inferior vesical vessels can easily bleed if care is not taken while dissecting this delicate plane. If a hematoma develops and is stable in size, it can be left in place. Bleeding must be controlled for any hematoma that is expanding; severe bleeding may require hypogastric artery ligation on the ipsilateral side. Opening and draining a significant and expanding hematoma will rarely reveal the source of active bleeding.",
"   </p>",
"   <p>",
"    Postoperatively, if the patient has a vaginal hematoma or vaginal bleeding beyond minimal staining, a vaginal pack may be placed. A bladder catheter should also be placed to prevent associated urinary retention. Vaginal packing should be removed within 24 hours. If brisk vaginal bleeding persists, the patient should be returned to the operating room to identify the source and control the bleeding. If there is only a small volume of ongoing bleeding, the patient may be observed with assessment of vital signs, pad counts, and serial hemoglobin levels.",
"   </p>",
"   <p>",
"    A stable hematoma will eventually resolve and may be managed expectantly. Drainage of a hematoma should be avoided, if possible, since this can introduce infection. For patients with severe pain, or who form an abscess within the hematoma, drainage is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1243226\">",
"    <span class=\"h3\">",
"     Wound breakdown or infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with wound breakdown or infection after anterior colporrhaphy will often complain of pain, bleeding, persistent serosanguineous or purulent discharge, and, in some cases, dyspareunia. For suture-only procedures, cases of wound breakdown can be allowed to heal by secondary intention. Wound infection is diagnosed based upon a finding of surrounding erythema and tenderness. Induration or a purulent discharge may also be present. Fever will develop in some, but not most patients. In cases of infection, the wound should be irrigated and the patient treated with an antibiotic with skin flora coverage (eg, a cephalosporin). Debridement may sometimes be required to remove excessive necrotic tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1243202\">",
"    <span class=\"h3\">",
"     Urinary tract issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystotomy may occur and is usually recognized intraoperatively. Urethral injury and ureteral injury are rare. Management of urinary tract injury during gynecologic surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary tract infection is common after anterior colporrhaphy and should be treated, as appropriate. Some women develop urinary retention postoperatively. This will typically resolve within several days and is managed by replacing the bladder catheter and then doing voiding trials to assess bladder function. Management of this issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=see_link&amp;anchor=H4701484#H4701484\">",
"     \"Stress urinary incontinence in women: Retropubic midurethral slings\", section on 'Voiding dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    De novo or worsening detrusor overactivity may develop in some women. Management of this condition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1243237\">",
"    <span class=\"h3\">",
"     Mesh-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a variety of potential complications related to transvaginal placement of reconstructive materials, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mesh exposure &ndash; This typically presents with vaginal pain or bleeding, but may be asymptomatic. Exposed mesh may become infected.",
"     </li>",
"     <li>",
"      Mesh contraction &ndash; The typical presentation is vaginal pain; bleeding is not commonly associated with mesh contraction. On examination, there is generally severe pain on palpation at the site of the mesh and a visible stricture of vaginal mucosa over the tissue, but usually no visible mesh.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain or infection may occur in the absence of mesh exposure or contraction. Women with complaints of vaginal bleeding or pain following transvaginal placement of reconstructive materials should be evaluated for mesh-related complications.",
"   </p>",
"   <p>",
"    In general, mesh-related complications are managed surgically with mesh excision. In cases of mesh erosion, the exposed mesh should be excised. Some surgeons may attempt to avoid excision areas of small mesh erosions (&lt;0.5 cm) by returning to the operating room, mobilizing the mucosal edges surrounding the erosion and closing the vaginal mucosa over the site. In our experience, such attempts are often not successful and many patients ultimately require mesh excision. &nbsp;",
"   </p>",
"   <p>",
"    Following mesh excision, if there are no symptoms or signs of infection, the defect may be closed. If infection is suspected, the site where mesh was removed should be left open to heal by secondary intention and broad-spectrum antibiotics given. In our practice, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    since they offer broad spectrum oral coverage including anaerobes. Particularly after mesh kit placement, removal of all mesh is technically difficult and may result in further complications. Although infected mesh tends to come out easily with gentle traction, aggressive dissection to remove mesh that is not involved and is deeper in the pelvis is discouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365169\">",
"    <span class=\"h3\">",
"     Vaginal pain or dyspareunia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incisional pain typically resolves two to four weeks after the procedure. In some women, vaginal pain continues, particularly dyspareunia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/43\">",
"     43",
"    </a>",
"    ]. In some cases, postoperative vaginal narrowing may be excessive, and vaginal dilation or lysis of adhesions can be performed to facilitate intercourse and pelvic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19855121\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior colporrhaphy is associated with high prolapse recurrence rates, especially if apex or lateral defect is not repaired when indicated. Prospective studies regarding traditional colporrhaphy have reported a wide range of success rates at one- to two-year follow-up, 37 to 83 percent, the lower limit of which is unacceptably low [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1936017\">",
"    <span class=\"h3\">",
"     Use of reconstructive materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;POP repair with transvaginal placement of reconstructive materials (permanent or absorbable mesh or biografts) has gained popularity in recent years. For anterior prolapse repair, reconstructive materials are available in two general forms, either as a piece that is tailored by the surgeon for the individual patient intraoperatively or as a pre-cut mesh kit.",
"   </p>",
"   <p>",
"    For women undergoing primary anterior colporrhaphy, we suggest native tissue repair rather than use of reconstructive materials. An increase in long-term efficacy and patient satisfaction with use of reconstructive materials has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Available data show that these materials are associated with increased rates of complications and increased cost [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/52-56\">",
"     52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of reconstructive materials by surgeons experienced with the specific procedure is a reasonable option for women with factors that increase the risk of prolapse recurrence (eg, recurrent prolapse, obesity, large anterior wall defects). Such use should be individualized and surgeons should counsel patients about the lack of efficacy and safety data and about alternative treatments. This is consistent with recommendations from the American College of Obstetricians and Gynecologists (ACOG) and the American Urogynecologic Society (AUGS) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A short-term improvement in efficacy with use of surgeon-tailored reconstructive materials for anterior vaginal wall prolapse was found in a meta-analysis of 10 randomized trials that found a significantly lower risk of objective recurrence of anterior prolapse, at one-year follow-up, following use of absorbable synthetic mesh (OR 0.44, 95% CI 0.21-0.89; 24 versus 43 percent) or a biograft (OR 0.56, 95% CI 0.34-0.92; 14 versus 22 percent) compared with traditional anterior colporrhaphy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/58\">",
"     58",
"    </a>",
"    ]. The meta-analysis did not report complications rates.",
"   </p>",
"   <p>",
"    Similarly, pre-cut mesh kits have been found to have better short-term objective cure rates than native tissue colporrhaphy, based upon randomized trial data [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/43,59-61\">",
"     43,59-61",
"    </a>",
"    ]. In the largest trial, at one-year follow-up, significantly more women in the mesh kit group achieved a composite objective and subjective measure of success (61 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/60\">",
"     60",
"    </a>",
"    ]. However, mesh kit repair resulted in a higher frequency of complications, including hemorrhage, bladder perforation, mesh exposure, and dyspareunia.",
"   </p>",
"   <p>",
"    There are few data comparing use of surgeon-tailored materials with pre-cut mesh kits. Observational data regarding these techniques have found similar rates of prolapse recurrence (10 and 14 percent) and mesh extrusion (11 and 13 percent), based upon a meta-analysis of 18 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications related to use of reconstructive materials are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2538188\">",
"    <span class=\"h1\">",
"     PROCEDURES NO LONGER ROUTINELY PERFORMED",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Paravaginal defect repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paravaginal repair involves reattaching the lateral vagina to the pelvic sidewall. This procedure is rarely performed in current practice, since it has not been found to improve the outcomes for which it was originally intended, anterior vaginal wall prolapse and stress urinary incontinence (SUI).",
"   </p>",
"   <p>",
"    Most women with anterior vaginal wall prolapse also have prolapse of the vaginal apex. Apical repair procedures (eg, sacral colpopexy) alone have been found to correct anterior prolapse as effectively as apical repair combined with paravaginal repair, based upon observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]; no randomized trials have addressed this issue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=see_link&amp;anchor=H680302#H680302\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Abdominal route'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paravaginal repair was originally thought to also be a treatment for SUI, but it does not appear to be an effective procedure for this indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H9#H9\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Procedures no longer recommended'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Repair of other site-specific defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse vaginal wall defects are typically corrected with procedures that are usually considered operations for prolapse of the vaginal apex, including sacral colpopexy or uterosacral ligament fixation. Apical and anterior vaginal prolapse often coexist and likely share a common pathogenesis, as noted above. (See",
"    <a class=\"local\" href=\"#H2157046\">",
"     'Concomitant repair of other sites of prolapse'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H17#H17\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Abdominal sacral colpopexy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H8286327#H8286327\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Uterosacral ligament suspension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support procedures performed for a significant anterior vaginal wall and apical defect are generally performed in the routine fashion, although a slightly lower dissection on the anterior vaginal wall from the apex may be performed to insure adequate anterior wall support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365214\">",
"    <span class=\"h2\">",
"     Bladder function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most surgeons leave a bladder catheter in place following anterior colporrhaphy or any major pelvic surgery, since many women have transient voiding dysfunction immediately after surgery. We remove the catheter on the first postoperative day and check a postvoid residual after the patient&rsquo;s first void. A postvoid residual greater than 100 mL is considered abnormal. Patients with elevated postvoid residuals should continue mechanical bladder drainage either via continuous transurethral Foley catheter or intermittent self-catheterization until postvoid residuals are consistently less than 100 mL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Discharge medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that postoperative vaginal estrogen therapy expedites healing of vaginal incisions and also prevents the occurrence of urinary tract infection in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. We prescribe 1 gram of conjugated estrogens cream at bedtime three nights per week for six weeks. A dose of 1 gram estrogen cream vaginally at bedtime for two weeks in non-postoperative patients and for four to six weeks in patients postvaginal reconstructive surgery may be initiated immediately after surgery. Use of 1 gram of estrogen cream at bedtime three nights per week can then be used for maintenance therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Activity restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to support any particular activity restrictions, but surgeons commonly restrict postoperative activities such as sexual activity or putting anything (other than physician ordered medication) in the vagina. Many physicians also suggest that patients avoid weight lifting greater than 5 lbs, straining with bowel movements, and activities associated with sudden or repetitive increases in intraabdominal pressure (ie, jogging, heavy weight lifting) for at least six weeks after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Return to work",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients generally feel able to return to work three to four weeks after an isolated anterior vaginal wall defect repair, although we ask them to continue the activity restrictions described above for a total of six weeks. Based on the extent of concomitant procedures and type of employment, patients may need to be on medical leave for six weeks, however, most surgeons agree that vaginal surgery may require allowing a faster return to work after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/8/7306/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior vaginal wall prolapse describes support abnormalities of the anterior wall of the vagina. Prolapse of the anterior wall typically coexists with prolapse at other anatomic sites, especially the apex (vaginal apex, posterior vaginal wall). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of anterior vaginal wall prolapse is thought to be defects at specific sites of the support structures, rather than an overall stretch of the anterior wall. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis of anterior wall defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative evaluation of women with anterior vaginal defects included identification of the specific site(s) of anterior defects as well as prolapse at other anatomic sites. (See",
"      <a class=\"local\" href=\"#H4650631\">",
"       'Candidates for anterior prolapse repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing surgical repair on anterior vaginal wall prolapse, we recommend antibiotic prophylaxis for surgical site infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25711799\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anterior colporrhaphy is performed to correct midline defects and is typically performed transvaginally. Anterior colporrhaphy is only moderately effective for repair of anterior vaginal wall prolapse. Success rates of anterior colporrhaphy range from 37 to 83 percent. (See",
"      <a class=\"local\" href=\"#H1936642\">",
"       'Midline defect repair (anterior colporrhaphy)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing primary anterior colporrhaphy, we suggest native tissue repair rather than use of reconstructive materials (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Use of reconstructive materials by surgeons experienced with the specific procedure is a reasonable option for women with factors that increase the risk of prolapse recurrence (eg, recurrent prolapse, obesity, large anterior wall defects). Such use should be individualized and surgeons should counsel patients about the lack of efficacy and safety data and about alternative treatments. (See",
"      <a class=\"local\" href=\"#H1936017\">",
"       'Use of reconstructive materials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/1\">",
"      Rooney K, Kenton K, Mueller ER, et al. Advanced anterior vaginal wall prolapse is highly correlated with apical prolapse. Am J Obstet Gynecol 2006; 195:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/2\">",
"      Brincat CA, Larson KA, Fenner DE. Anterior vaginal wall prolapse: assessment and treatment. Clin Obstet Gynecol 2010; 53:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/3\">",
"      Jones KA, Shepherd JP, Oliphant SS, et al. Trends in inpatient prolapse procedures in the United States, 1979-2006. Am J Obstet Gynecol 2010; 202:501.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/4\">",
"      Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979-1997. Am J Obstet Gynecol 2003; 188:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/5\">",
"      Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/6\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     Pilia-Allen, A, Benson, J. Cystocele. In: The female pelvic floor: Disorders of function and support, Brubaker, L, Saclarides, T (Eds), F.A. Davis, Philadelphia 1996. p. 269.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/8\">",
"      Nichols DH, Milley PS, Randall CL. Significance of restoration of normal vaginal depth and axis. Obstet Gynecol 1970; 36:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/9\">",
"      Weber AM, Walters MD. Anterior vaginal prolapse: review of anatomy and techniques of surgical repair. Obstet Gynecol 1997; 89:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/10\">",
"      Boyles SH, Edwards SR. Repair of the anterior vaginal compartment. Clin Obstet Gynecol 2005; 48:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/11\">",
"      Oelrich TM. The striated urogenital sphincter muscle in the female. Anat Rec 1983; 205:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/12\">",
"      Graves EJ, Gillum BS. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1995. Vital Health Stat 13 1997; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/13\">",
"      White GR. Cystocele--a radical cure by suturing lateral sulci of the vagina to the white line of pelvic fascia. 1909. Int Urogynecol J Pelvic Floor Dysfunct 1997; 8:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/14\">",
"      White GR. An anatomical operation for the cure of cystocele. Am J Obstet Dis Women Child 1912; 65:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/15\">",
"      Delancey JO. Fascial and muscular abnormalities in women with urethral hypermobility and anterior vaginal wall prolapse. Am J Obstet Gynecol 2002; 187:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/16\">",
"      Beck RP, McCormick S. Treatment of urinary stress incontinence with anterior colporrhaphy. Obstet Gynecol 1982; 59:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/17\">",
"      Richardson AC, Lyon JB, Williams NL. A new look at pelvic relaxation. Am J Obstet Gynecol 1976; 126:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/18\">",
"      Richardson AC, Edmonds PB, Williams NL. Treatment of stress urinary incontinence due to paravaginal fascial defect. Obstet Gynecol 1981; 57:357.",
"     </a>",
"    </li>",
"    <li>",
"     Benson, J. Female pelvic floor disorders: Investigation and management, WW Norton &amp; Company, New York 1992.",
"    </li>",
"    <li>",
"     Nichols, D, Randall, C. Vaginal surgery, Williams and Wilkins, Baltimore 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/21\">",
"      Maher CF, Feiner B, DeCuyper EM, et al. Laparoscopic sacral colpopexy versus total vaginal mesh for vaginal vault prolapse: a randomized trial. Am J Obstet Gynecol 2011; 204:360.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/22\">",
"      Rooney, K, Mueller, E, Kenton, K, et al. Can advanced stages of anterior or posterior vaginal wall prolapse occur without apical involvement? J Pelvic Surgery 2006; 12:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/23\">",
"      Elkadry EA, Kenton KS, FitzGerald MP, et al. Patient-selected goals: a new perspective on surgical outcome. Am J Obstet Gynecol 2003; 189:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/24\">",
"      Hullfish KL, Bovbjerg VE, Steers WD. Patient-centered goals for pelvic floor dysfunction surgery: long-term follow-up. Am J Obstet Gynecol 2004; 191:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/25\">",
"      Mahajan ST, Elkadry EA, Kenton KS, et al. Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. Am J Obstet Gynecol 2006; 194:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/26\">",
"      Brubaker, L, Norton, P. Current Clinical Nomenclature for Description of Pelvic Organ Prolapse. Journal of Pelvic Surgery 1996; 2:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/27\">",
"      Madjar S, Frischer Z, Nieder AM, Waltzer WC. Bladder wall abscess following midurethral sling procedure. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/28\">",
"      Lee SY, Kim JY, Park SJ, et al. Bilateral recurrent thigh abscesses for five years after a transobturator tape implantation for stress urinary incontinence. Korean J Urol 2010; 51:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/29\">",
"      DeSouza R, Shapiro A, Westney OL. Adductor brevis myositis following transobturator tape procedure: a case report and review of the literature. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/30\">",
"      Connolly TP. Necrotizing surgical site infection after tension-free vaginal tape. Obstet Gynecol 2004; 104:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/31\">",
"      Sivanesan K, Abdel-Fattah M, Tierney J. Perineal cellulitis and persistent vaginal erosion after transobturator tape (Obtape)--case report and review of the literature. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/32\">",
"      Karsenty G, Boman J, Elzayat E, et al. Severe soft tissue infection of the thigh after vaginal erosion of transobturator tape for stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/33\">",
"      Harmanli O, Boyer RL, Metz S, et al. Double-blinded randomized trial of preoperative antibiotics in midurethral sling procedures and review of the literature. Int Urogynecol J 2011; 22:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/34\">",
"      Duff P, Park RC. Antibiotic prophylaxis in vaginal hysterectomy: a review. Obstet Gynecol 1980; 55:193S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/35\">",
"      Mittendorf R, Aronson MP, Berry RE, et al. Avoiding serious infections associated with abdominal hysterectomy: a meta-analysis of antibiotic prophylaxis. Am J Obstet Gynecol 1993; 169:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/36\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.",
"     </a>",
"    </li>",
"    <li>",
"     American Urologic Association: Urologic surgery antimicrobial prophylaxis file://www.auanet.org/content/media/antimicroprop08.pdf (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/38\">",
"      Quadri G, Magatti F, Belloni C, Mattioli G. Transabdominal repair of cystocele by wedge colpectomy during combined abdominal-vaginal surgery. Int Urogynecol J Pelvic Floor Dysfunct 1997; 8:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/39\">",
"      Lovatsis D, Drutz HP. Is transabdominal repair of mild to moderate cystocele necessary for correction of prolapse during a modified Burch procedure? Int Urogynecol J Pelvic Floor Dysfunct 2001; 12:193.",
"     </a>",
"    </li>",
"    <li>",
"     Walsh CJ, Wall L. \"Anterior Compartment\" Pelvic Reconstructive Surgery, Stanton SL, Zimmern P.  (Eds), Springer-Verlag, London 2005. p.161.",
"    </li>",
"    <li>",
"     Walters MD. Surgical correction of anterior vaginal wall prolapse. In: Urogynecology and Reconstructive Pelvic Surgery, 3, Walters MD, Karram MM.  (Eds), Mosby Elsevier, Philadelphia 2007. p.234.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/42\">",
"      Feiner B, Maher C. Vaginal mesh contraction: definition, clinical presentation, and management. Obstet Gynecol 2010; 115:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/43\">",
"      Vollebregt A, Fischer K, Gietelink D, van der Vaart CH. Primary surgical repair of anterior vaginal prolapse: a randomised trial comparing anatomical and functional outcome between anterior colporrhaphy and trocar-guided transobturator anterior mesh. BJOG 2011; 118:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/44\">",
"      Sand PK, Koduri S, Lobel RW, et al. Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles. Am J Obstet Gynecol 2001; 184:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/45\">",
"      Weber AM, Walters MD, Piedmonte MR, Ballard LA. Anterior colporrhaphy: a randomized trial of three surgical techniques. Am J Obstet Gynecol 2001; 185:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/46\">",
"      Gandhi S, Goldberg RP, Kwon C, et al. A prospective randomized trial using solvent dehydrated fascia lata for the prevention of recurrent anterior vaginal wall prolapse. Am J Obstet Gynecol 2005; 192:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/47\">",
"      Meschia M, Pifarotti P, Bernasconi F, et al. Porcine skin collagen implants to prevent anterior vaginal wall prolapse recurrence: a multicenter, randomized study. J Urol 2007; 177:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/48\">",
"      Guerette NL, Peterson TV, Aguirre OA, et al. Anterior repair with or without collagen matrix reinforcement: a randomized controlled trial. Obstet Gynecol 2009; 114:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/49\">",
"      Murphy M, Society of Gynecologic Surgeons Systematic Review Group. Clinical practice guidelines on vaginal graft use from the society of gynecologic surgeons. Obstet Gynecol 2008; 112:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/50\">",
"      Sung VW, Rogers RG, Schaffer JI, et al. Graft use in transvaginal pelvic organ prolapse repair: a systematic review. Obstet Gynecol 2008; 112:1131.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.icsoffice.org/Publications/ICI_4/files-book/comite-15.pdf (Accessed on January 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/52\">",
"      Maher C, Baessler K, Glazener CM, et al. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev 2007; :CD004014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/53\">",
"      de Tayrac R, Devoldere G, Renaudie J, et al. Prolapse repair by vaginal route using a new protected low-weight polypropylene mesh: 1-year functional and anatomical outcome in a prospective multicentre study. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/54\">",
"      Sivaslioglu AA, Unlubilgin E, Dolen I. A randomized comparison of polypropylene mesh surgery with site-specific surgery in the treatment of cystocoele. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/55\">",
"      Hiltunen R, Nieminen K, Takala T, et al. Low-weight polypropylene mesh for anterior vaginal wall prolapse: a randomized controlled trial. Obstet Gynecol 2007; 110:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/56\">",
"      Jia X, Glazener C, Mowatt G, et al. Efficacy and safety of using mesh or grafts in surgery for anterior and/or posterior vaginal wall prolapse: systematic review and meta-analysis. BJOG 2008; 115:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/57\">",
"      Committee on Gynecologic Practice. Committee Opinion no. 513: vaginal placement of synthetic mesh for pelvic organ prolapse. Obstet Gynecol 2011; 118:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/58\">",
"      Foon R, Toozs-Hobson P, Latthe PM. Adjuvant materials in anterior vaginal wall prolapse surgery: a systematic review of effectiveness and complications. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/59\">",
"      Nguyen JN, Burchette RJ. Outcome after anterior vaginal prolapse repair: a randomized controlled trial. Obstet Gynecol 2008; 111:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/60\">",
"      Altman D, V&auml;yrynen T, Engh ME, et al. Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse. N Engl J Med 2011; 364:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/61\">",
"      Withagen MI, Milani AL, den Boon J, et al. Trocar-guided mesh compared with conventional vaginal repair in recurrent prolapse: a randomized controlled trial. Obstet Gynecol 2011; 117:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/62\">",
"      Murray S, Haverkorn RM, Lotan Y, Lemack GE. Mesh kits for anterior vaginal prolapse are not cost effective. Int Urogynecol J 2011; 22:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/63\">",
"      Shippey SH, Quiroz LH, Sanses TV, et al. Anatomic outcomes of abdominal sacrocolpopexy with or without paravaginal repair. Int Urogynecol J 2010; 21:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/64\">",
"      Lowder JL, Park AJ, Ellison R, et al. The role of apical vaginal support in the appearance of anterior and posterior vaginal prolapse. Obstet Gynecol 2008; 111:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/65\">",
"      Callens A, Vaillant L, Lecomte P, et al. Does hormonal skin aging exist? A study of the influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques. Dermatology 1996; 193:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/66\">",
"      Maheux R, Naud F, Rioux M, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/67\">",
"      Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/8/7306/abstract/68\">",
"      Knoepp LR, Bracken JN, Hoskey KA, et al. Post-operative instructions: Is there a consensus within the realm of urogynecology? Fem Pelvic Med Reconstr Surg 2011; 17:S31.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8084 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-7C4F869326-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7306=[""].join("\n");
var outline_f7_8_7306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1630899\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1631916\">",
"      ANATOMY AND MECHANISMS OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Normal anterior wall support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis of anterior wall defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Site-specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4650631\">",
"      CANDIDATES FOR ANTERIOR PROLAPSE REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2157028\">",
"      SURGICAL PLANNING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2157038\">",
"      Site-specific repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2157046\">",
"      Concomitant repair of other sites of prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4650894\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4650902\">",
"      Informed consent and patient goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4650910\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4650918\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1934772\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25711790\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25711799\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25712025\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25712074\">",
"      Other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1936642\">",
"      MIDLINE DEFECT REPAIR (ANTERIOR COLPORRHAPHY)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19854837\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1636600\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1243210\">",
"      - Hemorrhage or hematoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1243226\">",
"      - Wound breakdown or infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1243202\">",
"      - Urinary tract issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1243237\">",
"      - Mesh-related complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H365169\">",
"      - Vaginal pain or dyspareunia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19855121\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1936017\">",
"      - Use of reconstructive materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2538188\">",
"      PROCEDURES NO LONGER ROUTINELY PERFORMED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Paravaginal defect repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Repair of other site-specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365214\">",
"      Bladder function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Discharge medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Activity restrictions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Return to work",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8084|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/63/32756\" title=\"figure 1\">",
"      Female pelvic muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/63/15349\" title=\"figure 2\">",
"      Pelvic organ prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/29/16852\" title=\"figure 3\">",
"      Sites anter vaginal defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/54/15202\" title=\"figure 4\">",
"      Sites pelvic organ support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/1/3100\" title=\"figure 5\">",
"      Three by three grid POP-Q",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/23/13684\" title=\"figure 6\">",
"      Vaginal anterior repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8084|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/62/20449\" title=\"picture 1\">",
"      Cystocele and rectocele",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=related_link\">",
"      Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=related_link\">",
"      Pelvic organ prolapse in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43607?source=related_link\">",
"      Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=related_link\">",
"      Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=related_link\">",
"      Stress urinary incontinence in women: Retropubic midurethral slings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=related_link\">",
"      Techniques to reduce blood loss during abdominal or laparoscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=related_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_8_7307="Congenital anomaly terminology";
var content_f7_8_7307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Terms used to describe congenital abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Term",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malformation",
"       </td>",
"       <td>",
"        Defects of organs or body parts due to an intrinsically abnormal developmental process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deformation",
"       </td>",
"       <td>",
"        Abnormalities of the position of body parts due to extrinsic intrauterine mechanical forces that modify a normally formed structure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disruption",
"       </td>",
"       <td>",
"        Defects of organs or body parts that result from destruction of or interference with normal development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysplasia",
"       </td>",
"       <td>",
"        Anomalies that result from the abnormal organization of cells into tissues",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7307=[""].join("\n");
var outline_f7_8_7307=null;
var title_f7_8_7308="Stages of aortic regurgitation";
var content_f7_8_7308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Echocardiographic stages of chronic aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Compensated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transitional",
"       </td>",
"       <td class=\"subtitle1\">",
"        Decompensated*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Dimensions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        End-diastolic dimension (mm)",
"       </td>",
"       <td>",
"        &lt;60",
"       </td>",
"       <td>",
"        60 to 70",
"       </td>",
"       <td>",
"        &gt;75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        End-systolic dimension (mm)",
"       </td>",
"       <td>",
"        &lt;45",
"       </td>",
"       <td>",
"        45 to 50",
"       </td>",
"       <td>",
"        &gt;55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Volumes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        End-diastolic volume (mL/m2)",
"       </td>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        130 to 160",
"       </td>",
"       <td>",
"        &gt;170",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        End-systolic volume (ml/m2)",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        50 to 60",
"       </td>",
"       <td>",
"        &gt;60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Left ventricular function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ejection fraction (percent)",
"       </td>",
"       <td>",
"        &gt;55",
"       </td>",
"       <td>",
"        51 to 55",
"       </td>",
"       <td>",
"        &le;50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fractional shortening (percent)",
"       </td>",
"       <td>",
"        &gt;32",
"       </td>",
"       <td>",
"        30 to 31",
"       </td>",
"       <td>",
"        &lt;29",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with intermediate values between transitional and decompensated disease (end-diastolic dimension 70 to 75 mm and end-systolic dimension 50 to 55 mm) can be referred for exercise testing. Those with an abnormal response are referred for valve replacement, while those with a normal response to exercise are closely monitored.",
"    <div class=\"footnotes\">",
"     * Patients with decompensated aortic regurgitation are referred for aortic valve replacement. Lower threshold values can be considered in patients of small stature.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7308=[""].join("\n");
var outline_f7_8_7308=null;
var title_f7_8_7309="Granulomatous diseases nose and sinuses";
var content_f7_8_7309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Granulomatous diseases of nose and paranasal sinuses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Granulomatous diseases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <em>",
"         Mycobacterial",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Tuberculosis (M. tuberculosis)",
"       </td>",
"       <td>",
"        PPD, CXR, QFT-G, AFB smear and culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Leprosy (M. leprae)",
"       </td>",
"       <td>",
"        Skin smear or biopsy, PCR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Atypical mycobacterial (eg, M. chelonei)",
"       </td>",
"       <td>",
"        AFB smear and culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <em>",
"         Treponemal",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Syphilis",
"       </td>",
"       <td>",
"        RPR, FTA-ABS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <em>",
"         Bacterial",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Rhinoscleroma (Klebsiella rhinoscleromatis)",
"       </td>",
"       <td>",
"        Culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <em>",
"         Fungal",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Histoplasmosis (Histoplasma capsulatum)",
"       </td>",
"       <td>",
"        Special stains, culture, serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <em>",
"         Protozoan",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Leishmaniasis (Leishmania braziliensis)",
"       </td>",
"       <td>",
"        Skin smear or aspirate, PCR, biopsy showing intra and extracellular Leishman bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Rhinosporidiosis (Rhinosporidium seeberi)",
"       </td>",
"       <td>",
"        Biopsy showing granulomas and typical sporangia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Vasculitides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"       <td>",
"        ANCA, biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Churg-Strauss syndrome",
"       </td>",
"       <td>",
"        Peripheral eosinophilia, ANCA, biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lethal midline granulomatosis (extranodal NK/T cell lymphoma)",
"       </td>",
"       <td>",
"        Biopsy showing polymorphous lymphoid infiltrate; immunophenotype positive for CD2, surface CD3, CD56; clonal EBV genomes present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonkeratinizing nasopharyngeal carcinoma",
"       </td>",
"       <td>",
"        Biopsy shows an epithelial neoplasm with a dense lymphoplasmacytic infiltrate (predominantly T cells); associated with EBV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        Biopsy showing noncaseating granulomas, CXR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cocaine-induced midline destructive lesion",
"       </td>",
"       <td>",
"        History of cocaine use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granulomatous rosacea",
"       </td>",
"       <td>",
"        Granulomatous perifolliculitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPD: purified protein derivative skin test; CXR: chest radiograph; QFT-G: Quantiferon-Gold; AFB: acid fast bacilli; PCR: polymerase chain reaction; RPR: rapid plasma reagin; FTA-ABS: fluorescent treponemal antibody absorption; ANCA: antineutrophil cytoplasmic antibody; EBV: Epstein Barr virus.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zargari O, Elpern DJ. Granulomatous diseases of the nose. Int J Dermatol 2009; 48:1275.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7309=[""].join("\n");
var outline_f7_8_7309=null;
var title_f7_8_7310="Genetic forms dystonia";
var content_f7_8_7310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic forms of dystonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Locus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Designation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mode of inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome, mutation and gene product",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT 1",
"       </td>",
"       <td>",
"        Early onset dystonia",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Typically begins in childhood; onset in limb often with progression to generalized dystonia",
"       </td>",
"       <td>",
"        9q34; GAG deletion in TOR1A gene causes abnormality in ATP-binding protein, torsinA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT2",
"       </td>",
"       <td>",
"        Autosomal recessive dystonia",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Childhood onset, generalized or segmental; Gypsy families",
"       </td>",
"       <td>",
"        Unknown chromosome, gene product",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT3",
"       </td>",
"       <td>",
"        X-linked dystonia-parkinsonism (Lubag)",
"       </td>",
"       <td>",
"        X-linked recessive",
"       </td>",
"       <td>",
"        Segmental or generalized dystonia with parkinsonism; predominantly in males from Panay island in Philippines",
"       </td>",
"       <td>",
"        Xq13.1; TAF1 gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT4",
"       </td>",
"       <td>",
"        Whispering dysphonia",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Laryngeal and cervical dystonia described in one Australian family",
"       </td>",
"       <td>",
"        Chromosomal location, gene and product unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        DYT5",
"       </td>",
"       <td>",
"        Dopa-responsive dystonia/parkinsonism",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Dystonia with or without parkinsonism; dramatic response to levodopa",
"       </td>",
"       <td>",
"        14q22; GCH1 locus; mutations in GTP cyclohydrolase I gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segawa syndrome",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Dystonia with or without parkinsonism; diurnal variation, with worst symptoms in evening; marked response to levodopa",
"       </td>",
"       <td>",
"        11p15.5; mutations in the tyrosine hydroxylase gene; tyrosine hydroxylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT6",
"       </td>",
"       <td>",
"        Adolescent onset dystonia of mixed type",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Mostly segmental dystonia; mixed limb, cervical, cranial; Amish-Mennonite, German, Irish, Italian families",
"       </td>",
"       <td>",
"        8p11.21; mutations in the THAP1 gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT7",
"       </td>",
"       <td>",
"        Adult onset focal dystonia",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Adult onset with cervical dystonia, limb dystonia, dysphonia, or blepharospasm; German family",
"       </td>",
"       <td>",
"        18p; gene and product unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT8",
"       </td>",
"       <td>",
"        Paroxysmal nonkinesigenic dyskinesia 1",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Episodes of dystonia/choreoathetosis not precipitated by exercise or activity",
"       </td>",
"       <td>",
"        2q35; myofibrillogenesis regulator (MR1 gene)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT9 (allelic with DYT18)",
"       </td>",
"       <td>",
"        Paroxysmal choreoathetosis with episodic spasticity and ataxia",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Episodes of dystonia, diplopia, and paresthesia with spastic paraplegia between attacks",
"       </td>",
"       <td>",
"        1p34.2; mutations in the SLC2A1 gene that encodes the glucose transporter type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT10",
"       </td>",
"       <td>",
"        Episodic kinesigenic dyskinesia 1 (paroxysmal kinesigenic dyskinesia)",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Episodic choreoathetosis and dystonia brought on by exercise/activity",
"       </td>",
"       <td>",
"        16p11.2; mutations in the PRRT2 gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT11",
"       </td>",
"       <td>",
"        Myoclonus-dystonia",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Myoclonic jerks associated with variable features of dystonia; very alcohol responsive",
"       </td>",
"       <td>",
"        7q; epsilon-sarcoglycan gene (SGCE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT12",
"       </td>",
"       <td>",
"        Rapid onset dystonia- parkinsonism",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Onset of dystonia and parkinsonism over days to months",
"       </td>",
"       <td>",
"        19q; ATP1A3 gene that encodes the Na+/K+ -ATPase alpha3 subunit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT13",
"       </td>",
"       <td>",
"        Multifocal and segmental dystonia",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Early adult onset segmental dystonia with cervical, cranial, and arm dystonia",
"       </td>",
"       <td>",
"        1p; gene and product unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT14",
"       </td>",
"       <td>",
"        Dopa responsive dystonia (now included under DYT5)",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Dystonia responsive to dopamine",
"       </td>",
"       <td>",
"        14q; gene and product unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT15",
"       </td>",
"       <td>",
"        Myoclonus-dystonia",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Myoclonus and dystonia",
"       </td>",
"       <td>",
"        18p; gene and product unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT16",
"       </td>",
"       <td>",
"        Early onset dystonia-parkinsonism",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Early onset generalized dystonia; some cases with parkinsonism unresponsive to levodopa",
"       </td>",
"       <td>",
"        2q31.3; PRKRA gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT17",
"       </td>",
"       <td>",
"        Adolescent onset",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Onset in neck with regional spread",
"       </td>",
"       <td>",
"        20p11.2-q13.12; gene and product unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT18 (allelic with DYT9)",
"       </td>",
"       <td>",
"        Paroxysmal choreoathetosis with episodic spasticity and ataxia",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Episodes of dystonia, diplopia, paresthesias with spastic paraplegia between attacks",
"       </td>",
"       <td>",
"        1p34.2; mutations in the SLC2A1 gene that encodes the glucose transporter type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT19",
"       </td>",
"       <td>",
"        Episodic kinesigenic dyskinesia&nbsp;2 (paroxysmal kinesigenic dyskinesia)",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Episodic choreoathetosis and dystonia brought on by exercise/activity",
"       </td>",
"       <td>",
"        16q13-q22.1; gene and product unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT20",
"       </td>",
"       <td>",
"        Paroxysmal nonkinesigenic dyskinesia 2",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Spontaneous episodes of dystonia",
"       </td>",
"       <td>",
"        2q31; gene and product unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DYT21",
"       </td>",
"       <td>",
"        Adolescent to adult onset",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Generalized or multifocal",
"       </td>",
"       <td>",
"        2q14.3-q21.3; gene and product unknown",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AD: autosomal dominant; AR: autosomal recessive; ATP: adenosine triphosphate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7310=[""].join("\n");
var outline_f7_8_7310=null;
var title_f7_8_7311="Sacroiliac tenderness III";
var content_f7_8_7311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Testing for sacroiliac pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the patient lying supine, he or she is instructed to flex one of the knees and then abduct as well as externally rotate the corresponding hip. Pressure on the flexed knee causes pain at the corresponding sacroiliac joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_8_7311=[""].join("\n");
var outline_f7_8_7311=null;
